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Abstract 
Eukaryotic cells possess a unique way to communicate with each other by passing 
metabolites and small molecules through protein pores that connect adjacent cells. Although 
there are many types and families of protein pores, connexins comprise a unique family.  Six 
connexin monomers assemble into a hemichannel, which is transported to the cell membrane. An 
opposing cell membrane containing compatible connexin hemichannels is located and connected, 
forming an intercellular dodecameric protein complex. This results in a protein channel that 
connects two separate cytoplasmic compartments to each other. This type of channel is known as 
a gap junction. 
   
Connexin expression and function is commonly tissue specific. Of the 21 known human 
connexins, less than half are currently well characterized. Three connexins are expressed in the 
lens, connexin 43 (Cx43), 46 (Cx46), and 50 (Cx50). Of these three, Cx46 and Cx50 both have 
major functions in the mature lens. Cx46 functions as a major gap junction channel, which 
maintains mature lens homeostasis, while Cx50 possesses growth control properties in the lens. 
Cx46 expression is modulated in breast and bone tumors, and during ischemia. 
 
It is hypothesized that Cx46 provides resistance to hypoxia mediated cell death by 
prolonging survival. In this study, Cx46 expression was detected in human Y79 retinoblastoma 
cells. Decreasing the expression of Cx46 in nude mice carrying Y79 xenografts slowed early 
stage tumor growth. Y79 cells in culture survive for over 72 hours in 1% oxygen in vitro. C46 
was upregulated in cultured lens cells when grown under hypoxia. Human lens epithelial cells, 
rabbit N/N1003A lens cells, and Y79 cells proliferated in 1% oxygen until Cx46 expression was 
depleted by use of siRNA. Protection from hypoxia-induced cell death was provided by 
transfection with the C-terminus of Cx46. We further determined that the promoter activity of 
Cx46 was increased in 1% oxygen. These results indicate that Cx46 would increase in response 
to hypoxia and suggest a role for Cx46 in protection from hypoxia. The studies demonstrate a 
novel function for Cx46 in cell survival during hypoxia. 
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Abstract 
Eukaryotic cells possess a unique way to communicate with each other by passing 
metabolites and small molecules through protein pores that connect adjacent cells. Although 
there are many types and families of protein pores, connexins comprise a unique family.  Six 
connexin monomers assemble into a hemichannel, which is transported to the cell membrane. An 
opposing cell membrane containing compatible connexin hemichannels is located and connected, 
forming an intercellular dodecameric protein complex. This results in a protein channel that 
connects two separate cytoplasmic compartments to each other. This type of channel is known as 
a gap junction. 
      
Connexin expression and function is commonly tissue specific. Of the 21 known human 
connexins, less than half are currently well characterized. Three connexins are expressed in the 
lens, connexin 43 (Cx43), 46 (Cx46), and 50 (Cx50). Of these three, Cx46 and Cx50 both have 
major functions in the mature lens. Cx46 functions as a major gap junction channel, which 
maintains mature lens homeostasis, while Cx50 possesses growth control properties in the lens. 
Cx46 expression is modulated in breast and bone tumors, and during ischemia. 
 
It is hypothesized that Cx46 provides resistance to hypoxia mediated cell death by 
prolonging survival. In this study, Cx46 expression was detected in human Y79 retinoblastoma 
cells. Decreasing the expression of Cx46 in nude mice carrying Y79 xenografts slowed early 
stage tumor growth. Y79 cells in culture survive for over 72 hours in 1% oxygen in vitro. C46 
was upregulated in cultured lens cells when grown under hypoxia. Human lens epithelial cells, 
rabbit N/N1003A lens cells, and Y79 cells proliferated in 1% oxygen until Cx46 expression was 
depleted by use of siRNA. Protection from hypoxia-induced cell death was provided by 
transfection with the C-terminus of Cx46. We further determined that the promoter activity of 
Cx46 was increased in 1% oxygen. These results indicate that Cx46 would increase in response 
to hypoxia and suggest a role for Cx46 in protection from hypoxia. The studies demonstrate a 
novel function for Cx46 in cell survival during hypoxia. 
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Preface 
“While it has been billions of years since the earth adopted oxygen as the substrate of life 
and hundreds of years since the scientific discovery of O2, our understanding of biological 
responses to hypoxia and their medical significance has greatly increased only within the last 
several decades. The rapid progress being made on so many fronts is remarkable and exciting. 
However, many challenges remain, the most obvious one being how to apply our growing 
knowledge of oxygen biology to the benefit of humankind, especially those who are suffering 
from chronic diseases such as cancer and cardiovascular diseases.”   
 
–Zhang and Semenza, 2008. (1)
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Chapter 1 - Literature Review 
 Eukaryotic Multicellular Communication 
Eukaryotic multicellular organisms communicate via a wide range of modalities.  
Diffusion works best in small multicellular organisms like insects, which do not have active 
transport mechanisms. The eukaryotic invertebrate C. elegans does not have a circulatory system 
but shares much of the same physiology of higher eukaryotes.  In this organism, cell-to-cell 
communication is promoted by a family of cell adhesion and integral membrane proteins called 
the innexins.  Innexins are believed to be the invertebrate version of connexins, both of which 
form functional gap junctions to exchange signals and metabolites (2, 3).  Invertebrates possess 
both innexins and pannexins, while vertebrates possess both pannexins and connexins (3, 4).  
Connexins, claudulins, occlaudulins, adherens, and other tight junction proteins are all integral 
membrane proteins (5).  Only two protein families form passive intercellular channels in 
vertebrates, the connexins and the pannexins.  Pannexins and innexins are structurally similar to 
connexins, but differ in their primary amino acid sequences, thus making them different families 
of proteins (3).  Connexin signaling is important for endocrine signaling throughout the body (6, 
7).  The focus of this thesis is on connexin signaling and function, especially during hypoxia. 
 Indirect Cell-to-Cell Communication – Paracrine and Endocrine Signaling 
Two forms of cellular signaling are important for vertebrate communication, near-range 
and long-range signaling (Figure 1.1).  Signals generated by one cell type that are received 
extracellularly by a nearby but different type of cell are of the paracrine signal type.  Signals 
created by one cell type but received extracellularly by a different cell type that is in a distant 
location is an example of endocrine signaling. Both types of signals must be released from a cell 
and traverse the extracellular milieu, be taken up by and then distributed by a transport system 
similar to the lymph or circulatory system to be effective.  Extracellular signals can be 
recognized by extracellular receptors, actively taken up by transporters, or diffuse freely into the 
cell and bind intracellular receptors, which activate or inhibit cellular responses.  Pannexins are 
reported to participate primarily in paracrine signaling through open hemichannels (8, 9).  This is 
distinct from the connexins, which often do not form open or functional hemichannels at the cell 
membrane (10, 11). 
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Figure 1.1 Schematic Overview of Multicellular Signaling 
Multicellular organisms use a variety of signaling mechanisms.  Endocrine signals are produced in one cell type then 
transported to a distant cell type via the bloodstream or a lymph system, and are often received in a receptor-
mediated fashion.  Paracrine signals are produced by cells and affect nearby cells of different types.  Autocrine 
signals produced by one cell affect the same cell or the same neighboring cell type.  Juxtacrine signals can be of the 
autocrine type, but generally involve physically interacting membrane proteins, which cause signal to be transduced 
within the cell.  Gap junctions generally participate in autocrine and juxtacrine signaling. 
 
 Direct Cell-to-Cell Communication –  
Juxtacrine Signaling: Cell Surface Proteins and Cellular Junctions 
Direct cell-to-cell communication can occur by two distinct mechanisms, autocrine 
signaling and juxtacrine signaling (Figure 1.1).  Autocrine signaling occurs when a cell produces 
a signal that acts upon the same cell type locally.  These signals can be released into the 
3 
extracellular matrix by transport protein systems, by vesicle release, or can pass to the adjacent 
cell through gap junction channels.  Autocrine signaling is often used in conjunction with gap 
junction channels (6, 12).  Juxtacrine signals are produced or received by cells that are in direct 
contact with each other.  Examples of juxtacrine signaling include the Notch signaling pathway, 
in which two cell membrane-localized receptors must physically interact to pass the signal; 
mechano-sensitive cell membrane channels, which release ions in response to stress; and, the 
signals that traverse gap junctions, such as calcium, in the heart.  One can realize the importance 
of gap junctions in relaying juxtacrine signals when observing heart activity.  Gap junctions, 
comprised of Cx43, can pass calcium signals that modulate heartbeat. Juvenile Cx43
-/-
 mice do 
not survive much past birth and the individual muscles of the heart cannot beat in a coordinated 
manner, which leads to death (13).   
 The Connexin Protein Family 
 Connexin Classification and Nomenclature 
Connexin classification and nomenclature is comprised of a gene name based on protein 
similarity, and the molecular weight of the connexin protein as predicted by its DNA sequence.  
Connexin proteins are divided into four categories, alpha, beta, gamma, and delta connexins.  
Each connexin gene is named for its subfamily and similarity, e.g. the human Connexin 46 gene 
is named GJA3, which is short for gap junction alpha 3. GJA3 protein has a predicted weight of 
46 kDa and is called hCx46 in the literature.  Mouse Cx46 is denoted as mCx46 and gja3.  GJB3, 
for example is a beta connexin; GJC3 a gamma connexin; GJD1 a delta connexin.  Alpha and 
beta connexins share high amino acid homology with other alpha and beta family members, 
respectively.  Gamma and delta connexins are comprised of connexins that do not share high 
homology with alpha or beta or each other.  The epsilon group of connexins contains only Cx23.  
Identification of all known connexin genes was accomplished by the availability of high quality 
nucleic acid sequence data.  The nomenclature is consistent with the declarations of the 
International Gap Junction Conference in Elsinore, Denmark, 2007 (14) and the HUGO database 
for gap junction proteins (http://www.genenames.org/genefamilies/GJ) as of January 2012.  The 
connexin gene families are given in Table 1.1. 
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Alpha Beta Gamma Delta Epsilon 
Cx37 Cx25 Cx30.2 Cx31.9 Cx23 
Cx40 Cx26 Cx45 Cx36  
Cx43 Cx30 Cx47 Cx40.1  
Cx46 Cx30.3    
Cx50 Cx31    
Cx59 Cx31.1    
Cx62 Cx32    
Table 1.1 Connexin Gene Families 
There are 5 gene families of connexins based on amino acid sequence similarity.  Data taken from the NCBI 
database, which can be found at http://www.ncbi.nlm.nih.gov/. 
 Transcription and Expression of Connexin Genes 
The rodent genome contains 20 confirmed, distinct and expressed connexin genes (15).  
The human genome contains 21 confirmed connexin genes and an unusual intron-less Cx43 
pseudogene.  General transcription processes are assumed to control the expression of all 
connexins.  Connexin expression is highly regulated in a spatial-temporal manor during many 
stages of physiological need including embryonic development (15-17), cellular health and tissue 
maintenance (15, 18-21), wound healing (22-24), and cancer progression (15, 19, 25-27).  
Connexin gene expression is limited by the transcription factors that are expressed in a given cell 
and is reviewed below.  Connexins can be controlled individually by proteins involved in the cell 
cycle and often influence the control of the cycle as well (5-7, 28).  Each tissue, and more 
specifically each cell type, can express a different combination of connexin genes to achieve the 
observed effect.  Each channel type has distinguishable electrophysiological characteristics and 
mixed connexin gap junctions can be distinguished from homomeric channels (29-31).   
Cx32 and Cx43 are two of the most ubiquitously expressed connexins.  Common and 
confirmed transcription factors that contribute to the expression of connexins in most tissues are 
SP1/SP3 and Activator Protein 1.  Cx43 is regulated by cAMP response elements and the Wnt 
and Ras-Raf-MAPK pathways (15). Since each connexin is expressed in only a subset of tissues, 
they are regulated by cell type specific transcription factors.  Examples include the cardiac 
Nkx2-5 TF that regulates the cardiac expression of Cx40, Cx43 and Cx45; activation and 
repression of Cx43 and Cx40 expression by the cardiac T-box TFs; GATA-4 that influences 
5 
heart, lung, liver, gonad, and gut specific gene expression, and does this with Cx40; liver-
specific HNF-1, which controls the expression of Cx32 and Mst-1 that aids in general organ 
development and influences Cx32 expression; Sox10 and Egr2/Krox20, which strongly regulate 
Cx31 and Cx32 in neuronal cells; estrogen, thyroid and parathyroid hormones that influence 
Cx43 expression in skeletal muscle; neuron-restrictive silencing factor that controls Cx36 in 
neurons; ciliary neurotrophic factor and related receptor control of Cx43 and Cx30 in the central 
nervous system (15); sheer stress in endothelial cells, which causes both a transient and long 
lived Cx40 mRNA up-regulation (32).  Table 1.2 illustrates the known roles of each connexin in 
human physiology based on confirmed information found in the NCBI databases as of January 
2012. 
The GJA3 gene, which encodes Cx46 protein, has a unique gene structure.  The average 
human gene contains 8-10 exons and 6-9 introns.  Roughly 5% of all introns in the genome are 
longer than 200,000 bp and 10% of all introns are larger than 11,000 bp (127).  The connexin 
family of genes generally contains 2 exons and a single intron.  The sole connexin 46 intron 
contains ~17,500 bp while exon 1 contains only the 5’ UTR, exon 2 contains the end of the 5’ 
UTR, the protein coding sequence, and the 3’ UTR. 
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Connexin 
Gene 
Connexin 
Name 
Tissue Location Ascribed Function Related Disease 
GJA6P Pseudogene X-linked, Not Expressed Unknown Unknown 
GJE1 Cx23 Buccal cells - Ear Unknown Nonsyndromic hearing loss 
GJB7 Cx25 Placenta
1
 Unknown Unknown 
GJB2 Cx26 
Inner Ear; hepatocytes, 
astrocytes, pancreas, 
testis
2
 
Ion homeostasis Pre-lingual deafness 
GJB6 Cx30 
Inner Ear; Skin/Follicles; 
Intestine; astrocytes, skin, 
kidney, mammary gland
2
 
Ion homeostasis 
Deafness; Hidrotic 
ectodermal dysplasia 2 
(alopecia); upregulated in 
gastric cancer 
GJC3 Cx30.2 
Inner Ear; pancreas, 
kidney, skeletal muscle, 
liver, placenta
1
; Neurons, 
conductive myocytes, 
testis
2
 
Ion homeostasis Nonsyndromic hearing loss 
GJB4 Cx30.3 
Skin; Thymocytes; Inner 
Ear 
Unknown 
Erythrokeratoderma without 
ataxia; hearing impairment 
GJB3 Cx31 
Inner Ear; Skin; 
Thymocytes; Neurons, 
testis
2
 
Proper epidermal 
keratinization; 
Neurite outgrowth 
Nonsyndromic deafness 
with neuropathy; 
Erythrokeratodermia 
variabilis 
GJB5 Cx31.1 
Skin
2
, Upper aerodigestive 
tract; Placenta 
Epidermis 
development; 
placental labyrinthine 
layer morphogenesis, 
placental 
spongiotrophoblast 
Gastric cancer 
7 
differentiation 
GJD3 Cx31.9 
Vascular smooth muscle 
cells; Cardiac tissue 
GJIC Unknown 
GJB1 Cx32 
Gastric tissue, Endothelial 
cells; oligodendrocytes, 
pancreas, testis and ovary, 
mammary gland, liver, 
kidney
2
 
Increases 
intercellular 
adhesion; 
maintenance of 
vascular function; 
Regulates cytokine 
expression 
CNS inflammation; X-
linked Charcot-Marie-Tooth 
disease; Gastric 
adenocarcinoma 
GJD2 Cx36 
CNS; Retina; Inferior 
olive of brainstem; 
Pancreatic beta cells; 
adrenal gland 
Passage of positively 
charged molecules 
Refractive errors; myopia; 
Juvenile myoclonic 
epilepsy; 
GJA4 Cx37 
Cardiac tissue; Platelets; 
Kidney glomeruli, ovary
2
 
Myoendothelial nitric 
oxide release; 
Platelet reactivity 
Increased risk of 
atherosclerosis and 
myocardial infarction; 
Increased ischemic damage 
spread; Tumor cell 
proliferation 
GJA5 Cx40 
Cardiac tissue; Kidney 
glomeruli 
Unknown Atrial fibrillation 
GJD4 Cx40.1 
Pancreas, kidney, skeletal 
muscle, liver, placenta, 
heart
1
 
Unknown Unknown 
GJA1 Cx43 
Ubiquitous; Cardiac; Lens, 
Skeleton 
Electrical 
conductance; Tissue 
homeostasis; Cancer 
activity 
Occulodentodigital 
dysplasia; Heart 
malformations; Associated 
with cancer progression 
GJC1 Cx45 
Smooth muscle; 
Myofibroblasts; Colon; 
GJIC; muscle 
contraction; synaptic 
Colorectal cancer silences 
GJC1 expression 
8 
Retina; Glomeruli, Bone transmission; 
vasculogenesis; 
visual perception 
GJA3 Cx46 Lens; Bone 
Tissue homeostasis 
and lens clarity 
Zonular pulverulent cataract 
type 3 
GJC2 Cx47 
CNS; astrocytes and 
oligodendrocytes 
Central and 
peripheral 
myelination, GJIC 
Pelizaeus-Merzbacher-like 
disease-1; lymphedema 
GJA8 Cx50 Lens; germ cells
2
 
Growth regulation; 
GIJC; Ion 
homeostasis 
Zonar pulverulent cataracts; 
nuclear progressive 
cataracts; cataract-
microcornea syndrome 
GJA9 Cx59 
Retina; testis, skeletal 
muscle
1
 
Unknown 
Distortion of visual 
perception 
GJA10 Cx62 
Retina; skeletal muscle, 
heart
1
 
Unknown 
Distortion of visual 
perception 
Table 1.2 Expressed Connexins in Human 
Data taken from NCBI database, 
1
Sohl et al., 2003 (33) and 
2
Bedner et al., 2011 (34).  Notice the varied distribution 
of connexins in human tissues and the general attribution of ion or tissue homeostasis.  Other non-channel functions 
of connexins remain to be identified. 
 Connexin Protein Structure 
All connexin proteins have a common 9 domain structure.  Each connexin contains an 
amino-terminal leader domain (AT), four intermembrane alpha helix domains (TM1-4), two 
extracellular loop domains (EL1-2), one intracellular loop domain (IL) and a carboxyl-terminal 
tail domain (CT).  EL1 and EL2 from each connexin protein form the 12 nodules of the docking 
face of the hexameric hemichannel.  Each extracellular loop contains at least one disulfide bridge 
proposed to stabilize the docking interface, highlighted by blue circles in Figure 1.2 (6).  The 
cysteines of the extracellular loops are highly conserved for the type of channels that gap 
junctions and the related pannexins and innexins form.  The amino-terminal domain contains a 
secretory signal sequence cleavage site predicted to occur between residues 41 and 42 
(AA41/E42D) by using both neural network and hidden Markov model modes of prediction 
trained on eukaryotes on the SignalP webserver (35).  This signal is not predicted on the 
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SecretomeP webserver, which predicts likelihood of a protein being secreated by non-classical 
secretion, such as with growth factors (36).  This would be expected of connexins since they are 
integral membrane proteins.  Connexins retain their signal sequences and are not cleaved upon 
insertion into the ER membrane, unlike other membrane proteins such as cadherins or G-protein 
coupled receptors (GPCRs).  The current hypotheses for the retention of the signal sequence is 
that it is used to alter gap junction gating and coupling in either a physical or electrostatic 
manner, or is used to direct post-translational insertion into the ER/Golgi membrane (37, 38).  
Interestingly, when both alpha and beta (Cx43 and Cx32, respectively) connexins were expressed 
in vitro using cRNAs as the source template in a liver-dervived microsome supplemented 
reticulocyte assay system, the signal sequences were recognized and, dependent on the signal 
recognition particle, subsequently cleaved by signal peptidase.  However, when these connexins 
were isolated from tissue sources the signal peptide was retained suggesting that connexins can 
follow the classical eukaryotic secretion system but fail to do so in vivo because of an unknown 
signal peptidase protection event (37, 39).  To date, the molecules needed for proper folding and 
membrane insertion of connexins remain to be identified. 
Connexins and innexins are non-glycosylated membrane proteins unlike the pannexins, 
which contain glycosylation consensus sequences and are glycosylated.  It is proposed that 
glycosylation prevents gap junction formation in the pannexin family (6).  Although connexins 
pass through the endoplasmic reticulum and the Golgi apparatus, they are not glycosylated but 
are phosphorylated during the normal life cycle (40).  Post-translational modifications that affect 
hemichannel and gap junction activity include phosphorylation, pH/electrostatic and redox 
effects, and S-nitrosylation (7, 41, 42).  The majority of modifications are made to the CT 
domain of the connexins.  The CT domain harbors the most sequence variability between each 
connexin and provides a way of molecular signal transduction and gating, which is different 
from the voltage gating properties that all connexins possess. 
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Figure 1.2 The Topology of Pannexin, Innexin, and Connexin Protein Families 
The topology of the connexin family is highly homologous to other protein families with similar function.  
Pannexins, innexins, and connexins share a common membrane topography. The 3 families of proteins that form 
channels permeable to second messengers and metabolites are integral, tetra-span membrane proteins. All members 
of the 3 families have their NH2 and COOH termini within the cytoplasm, and 2 extracellular loops that extend into 
the extracellular space. These loops contain 2 (pannexins and innexins) or 3 (connexins) highly conserved Cys 
residues (circles). Pannexins, but not innexins and connexins, feature a N-glycosylated branching on the second 
extracellular loop.  Reprinted with permission from APS: Bosco D, Haefliger J-A, Meda P. Connexins: Key 
Mediators of Endocrine Function. Physiol Rev 91: 1393–1445, 2011; doi:10.1152/physrev.00027.2010. 
 
 Biosynthesis and Trafficking of Connexins 
Connexins follow a unique maturation process for a transmembrane protein.  All 
connexins do not have a protein secretion signal sequence nor do they have membrane anchor 
sequences, and therefore do not follow the same pathway as a typical type III polytopic 
transmembrane protein that does have these features.  Connexins are generally synthesized by 
ribosomes on the endoplasmic reticulum (ER) and directly inserted into the ER membrane.  
However, unlike most integral membrane proteins, the connexins are oligomerized in the late 
compartments of the Golgi apparatus, termed the trans golgi network (TGN) (40, 43).  VanSlyke, 
Naus, and Musil (40) demonstrated that both alpha and beta connexins are synthesized as 
conformationally stable proteins within the ER but only oligomerize into a connexon once 
transported and localized to the TGN, prior to vesicle transport.  They also conclude that the 
Charcot–Marie–Tooth –X-linked (CMTX) disease causing mutants of Cx32 have an underlying 
defect in protein folding, and therefore do not exit endoplasmic reticulum associated degradation 
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(ERAD) quality control and do not subsequently oligomerize and traffic to the plasma 
membrane.  Exogenous overexpression of both alpha and beta connexins individually mediate an 
ER associated connexon forming pathway alternative to that of the TGN pathway commonly 
seen in connexin research (40, 44).  New connexons that pass quality control are packaged into 
vesicles and are transported to the edges of gap junction plaques and lipid rafts by microtubule-
assisted vesicle transport (45, 46). However, Cx26 can follow an unknown alternative transport 
pathway (46).  Connexins are synthesized, transported, assembled into plaques, then endocytosed 
and degraded by lysosomes in a matter of hours.  The average cellular half-life of intact connexin 
proteins is 1.5-4 hours (47).  Degradation pathways of connexins are dictated by interplay 
between phosphorylation and ubiquitination events that occur in the CT domain and lead to 
internalization of gap and/or annular junctions, and subsequent degradation by the proteasome 
and/or lysosomes, respectively, during normal cellular processes (47, 48), as illustrated in Figure 
1.3.   
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Figure 1.3 The Life Cycle of Connexin Proteins 
Connexins typically co-translationally insert into the ER. If properly folded, it is expected that connexins are spared from ERAD, 
whereas in other cases they may be targeted for ERAD. For at least some members of the connexin family, complete 
oligomerization is delayed until the connexin passes through the intermediate compartment and reaches the distal elements of the 
Golgi apparatus, namely the TGN (trans-Golgi network). Pleiomorphic vesicles and transport intermediates are thought to deliver 
closed connexons to the cell surface, a process that is facilitated by microtubules. Connexons may function as hemichannels and 
exchange small molecules with the extracellular environment or laterally diffuse in a closed state to sites of cell–cell apposition 
and dock with connexons from an opposing cell. In conjunction with cadherin-based cell adhesion, gap-junction channels cluster 
into plaques, open, and exchange secondary messengers. New gap-junction channels are recruited to the margins of gap-junction 
plaques and older channels are found in the centre of the plaques. Several connexin-binding proteins have been identified, and it 
is likely that one or more of these binding proteins regulate plaque formation and stability, possibly by acting as scaffolds to 
cytoskeletal elements. Gap-junction plaques and fragments of gap-junction plaques are internalized into one of two adjacent cells 
as a double-membrane structure commonly referred to as an annular junction, but renamed in the present review as 
connexosomes. Other pathways for connexin internalization may exist where connexons disassemble and enter the cell by 
classical endocytic pathways. Internalized gap junctions are targeted for degradation in lysosomes, although some evidence 
suggests a role in proteasomal degradation.  This figure and text was originally published in Biochemical Journal. Dale W. Laird, 
Life cycle of connexins in health and disease. Biochem.  J. 2006; 394: 527–543. Reproduced with permission © the Biochemical 
Society.  
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 Connexins Form Functional Transmembrane Protein Channels 
Six connexin proteins are co-translationally inserted within the endoplasmic reticulum 
membrane then transported through the Golgi apparatus to the late TGN compartment to be fully 
assembled into a connexon, depending on the subfamily type.  These six assembled connexins 
are referred to as connexons and hemichannels.  Hemichannels are formed when the connexon is 
trafficked to the cellular plasma membrane and is not met by an opposing cell membrane or 
connexon-containing lipid raft (37, 40, 49, 50) such as the apical surface of polarized epithelial 
cells.  A full gap junction channel is formed when one hemichannel is docked to an opposing 
hemichannel, resulting in an aqueous inner protein pore created by the number 2 and 3 
transmembrane spanning helices (TM2 and TM3) of each participating connexin (44, 51-53) and 
as seen in Figures 1.3 and 1.4.  It is assumed that water and small water soluble metabolites, 
including signaling molecules less than 1 kDa, flow freely through every gap junction (34, 54); 
signals that pass through connexins are discussed below.  It is known that siRNA moves through 
gap junctions as well (55). 
Gap junction channels can take multiple forms depending on the connexin expression 
pattern of the cell type.  Connexons made from a single connexin protein are termed homomeric.  
Mixtures of two or more connexins into a single connexon are given the term heteromeric.  
Apposing homomeric connexons are homotypic junctions and apposing heteromeric connexons 
are heterotypic junctions.  Annular junctions are formed when an entire 12-protein gap junction 
channel is internalized via a vesicle and degraded (34, 54).  Heterotypic gap junctions can be 
formed as illustrated in Table 1.3. 
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Figure 1.4 Connexins Form Functional Membrane Channels from Two Connexon Hemichannels 
Six connexins are oligomerized into a connexon hemichannel.  Each connexin subunit is differentially colored and 
labeled as in b.  PDB 2zw3.  Reprinted by permission from Macmillan Publishers Ltd: Nature 458, 597-602 (2 April 
2009) doi:10.1038/nature07869, copyright 2009. 
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Connexin 
Alpha Beta Gamma Delta Epsilon 
37 40 43 46 50 59 62 25 26 30 30.3 31 31.1 32 30.2 45 47 31.9 36 40.1 23 
A
lp
h
a
 
37 X X              X      
40 X X X             X      
43  X X X            X      
46   X X X                 
50     X                 
59      X X         X   X   
62      X X         X   X   
B
et
a
 
25        X              
26         X X  X  X        
30         X X  X  X        
30.3           X           
31         X X  X          
31.1             X         
32         X X    X        
G
a
m
m
a
 30.2 
              X   X    
45 X X X   X X         X   X   
47                 X     
D
el
ta
 
31.9               X   X    
36      X X         X   X   
40.1                    X  
E
p
si
lo
n
 
23                     X 
Table 1.3 Known Connexin Channel Forming Interactions 
Homotypic channel formation is assumed since each inter-channel interaction is unknown.  Data taken from NCBI 
database and can be found at http://www.ncbi.nlm.nih.gov/. 
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 Regulation of Connexin Function 
Connexins can be regulated in two primary ways.  The first and fastest way is through 
voltage-gating and electrostatic interactions (29, 53, 56, 57).  The second and slowest way is 
through signal transduction and protein modification such as phosphorylation (58), protein 
docking (4, 31, 59, 60), domain structure modification (61-64), and connexon mixing between 
cell and channel types (31, 34, 44, 65). 
Voltage-gating is the best known and easiest characteristic of gap junction channels to 
measure.  Voltage-gating of connexons can be accomplished in a number of ways as described 
below.  The presence of extracellular Ca
2+
 can induce changes in gap junction permeability.  The 
pH differences between the connected cells cytoplasm can induce closure of gap junction 
channels as well as create charge gradients (56, 66).  Gating by these mechanisms is governed by 
conformational changes in the pore, plug-gating, and/or loop-gating (29).  pH and calcium fluxes 
are a general process that occurs during ischemia and hypoxia, and will be discussed below. 
Phosphorylation, protein interaction and domain restructuring mainly regulate the 
stability and degradation of gap junction functions (47-49, 67, 68).  The mixing of connexins into 
connexons and gap junctions has profound effects on the regulation of gap junction activity as 
shown when Cx32 or Cx40 are co-expressed with endogenous Cx43 in NRK cells and Cx46 and 
Cx50 in lens cells (31, 69). However, not all groups of connexins mix, as seen in Table 1.3.  
Phosphorylation is by far the most common signal that connexins receive from the cell.  It is 
necessary for trafficking, gating, scaffolding, and degradation (38, 47, 68, 70, 71). 
 Cellular Functions of Connexins in Various Tissues and Associated Diseases 
As described above, connexins take on primary functions as voltage-gated gap junction 
channels, adhesion molecules, and as mediators of cellular homeostasis.  While the gating and 
adhesion properties of gap junctions are well known and assumed to function in healthy tissue, 
the effects of connexins on cellular homeostasis and growth differ with the cell type and 
connexin in question.  For example, gap junctions comprised of Cx43 in the heart confer the 
necessary voltage-gated channel properties needed for the heart to generate a coordinated beating 
rhythm.  In addition, Cx43 gap junctions in the majority of types of bone cells are necessary for 
proper growth control and development of bone (72-74).   
17 
Bone is a unique growth environment that is often hypoxic and unlike most other tissues.  
Gap junction hemichannels function in bone to release ATP and PGE2 in response to mechanical 
disruption, osteocytic network communication, cellular proliferation, differentiation, and survival 
(74, 75).  Cx40, Cx43, Cx45, and Cx46 are expressed in various bone cells.  Cx43 is expressed in 
every bone cell type and seems necessary since disruption of Cx43 has been linked to bone 
hypomineralization and a delay in ossification of the skeleton, which is seen in the partial 
phenocopies of human oculodentodigital dysplasia (ODDD) manifested in Cx43
-/-
 mice (75, 76).  
Cx45 is expressed in many cell types except tooth osteoblasts and osteoclasts.  It is up-regulated 
in response to a lack of Cx43 and is also known to inhibit the function of gap junction channels 
formed by Cx43 (74, 75).  Cx46 uniquely is expressed only in the cytoplasm and perinuclear area 
of osteoblasts and it fails to form functional gap junctions at the cell membrane (74, 75, 77).  
Interestingly, Cx43 has been shown to indirectly regulate gene transcription of many important 
molecules in bone development including osteocalcin, osteopontin, bone sialoprotein, alkaline 
phosphatase, RUNX2 transcription factor, and even the related bone connexins Cx45 and Cx46 
during development (74, 76).  
Cx26, Cx30, Cx30.3, Cx31are implicated in many forms of hearing loss and skin diseases 
(Table 1.2).  The epidermis expresses Cx26, Cx30, Cx30.3, Cx31.1, Cx37, and Cx43.  Follicular 
skin expresses Cx26, Cx30, Cx30.3, Cx31, Cx43, and Cx45.  Keratinocytes express Cx26, Cx30, 
Cx31, Cx37, Cx40, and Cx43 (22, 78).  Expression is dependent on the layer of skin in which the 
connexins are being expressed, which again indicates cell-type specific functions of the 
connexins.  Cx26 and Cx30 share similar functions in skin and have been implicated in 
controlling the proliferation, differentiation, and migration of keratinocytes.  Aberrant expression 
of these connexins results in slower wound closure and skin diseases caused by hyper-
proliferative cells with epidermal thickening and psoriasis (22).  Cx43 is known to be down-
regulated during wound closure and inhibition of Cx43 function speeds wound recovery time as 
seen with the pre-clinical candidate antisense oligodeoxynucleotide that targets Cx43 in skin 
epidermis and dermis tissues (24).  Additionally, knockdown of Cx43 protein expression results 
in Cx26 and Cx30 expression being increased, indicating functional redundancy in GJIC. But 
loss of Cx43 retained functional discrepancy in reducing cellular proliferation and migration (24, 
78).  Many parallels have been made between the function of connexins in the outer epidermal 
skin and in the lens, both tissues being devoid of blood vessels and lymph. 
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Mutant Cx30 gap junction channels cause hidrotic ectodermal dysplasia and play a 
critical role in hair follicle homeostasis (22).  Cx30.3 and Cx31 mutations are implicated in 
erythrokeratodermia variabilis and related skin disorders.  Mutations in Cx32 cause the neuronal 
sensory disease X-linked Charcot-Marie-Tooth disease by disrupting signals passed between 
Schwann cells and neurons.  In general, many mutations in disease causing connexin genes are 
causative of phenotypes in cell culture models, showing trafficking disorders, impaired gap 
junction activity, dominant negative effects on heterotypic junction activity, and the formation of 
leaky hemichannels (22).  
At least nine different connexins are expressed in the various tissues of the kidney: Cx26, 
Cx30.3, Cx31, Cx32, Cx37, Cx40, Cx43, Cx45, and Cx46 (79, 80).  Cx26 and Cx32 are co-
expressed in the proximal tubule.  The co-expression pattern is similar to that in the liver, 
stomach, and pancreas (79).  Cx26, Cx30, Cx32, Cx30.3, and Cx37 are considered the tubular 
connexins, while the remainders are part of the vasculature.  The only known phenotype 
associated with the tubular connexin knockout mice is prevalence of salt sensitive hypertension 
in Cx30
-/-
 mice (79).  In the renal vasculature, Cx40 plays a major role in the negative-feedback 
loop of renin secretion and detection of blood pressure.  Only Cx43 can modulate renin secretion 
correctly as demonstrated by knock-in studies (34).  In the case of Cx40
-/-
 mice, severe 
hypertension is attributed to the function of Cx40 as a scaffolding protein rather than a functional 
gap junction.  However correct Cx40 gap junction function is needed for proper renin secreting 
cell development and to turn off renin production (79). 
There are many CNS disorders caused by mutations in connexins.  Cx32 and Cx47 are 
implicated in the majority of nervous disorders, which all have defects in sensory defects.  In 
glial cells, structural and homeostatic functions have been ascribed to Cx32, Cx43, and Cx47.  
Interestingly, loss of Cx47 gap junctions in Cx47
-/-
 mice leads to repression of oligodendrocyte 
differentiation, development, and proliferation due to the loss of scaffolding function and 
subsequent aberrant transcription factor accumulation under non-inducing conditions (81).  Two 
known astrocyte connexins, Cx43 and Cx30, aid in the recovery of stimulus-induced ion flux by 
relocating potassium from the extracellular space into the cell via hemichannels (34, 81).  Again, 
connexins are demonstrated to have a variety of functions in every tissue examined to date. 
The knowledge of tissue specific connexins and sequencing of disease-associated 
connexin genes provides evidence that connexins are diverse proteins whose channel function is 
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not always as important as the scaffolding, structural, or other intracellular functions.  Evidence 
of this comes from functional redundancy and cell-specific ablation studies as discussed above.  
One specific tissue which expresses three types of connexins, the vertebrate lens, allows for the 
deciphering of well-defined roles in the function of each expressed connexin.  These roles have 
been assigned through the use of genetically modified mouse strains with various knockouts and 
knock-ins of the lens connexin genes complimented by in vivo phenotype analysis, and in vitro 
cell biology and electrophysiology studies.  
 Functional Role of Connexins in the Lens 
Three connexins are fully expressed in the mammalian lens tissue and each plays a 
specialized role.  Figure 1.5 illustrates that the expression of Cx43, Cx46 and Cx50 changes with 
the stage of differentiation of different regions of the lens.  Through the use of gene knockout 
and knock-in technology, connexins in the mouse lens have been extensively studied.  Without 
this technology, insights into the circulatory system of the lens would not have been made.  The 
lens is a naturally avascular and hypoxic tissue.  It must remain hypoxic and devoid of 
vasculature to maintain clarity and function.  The mature fiber cells of the lens, the oldest of the 
lens cells and the most centrally located, remain alive and functional by maintaining a low level 
of anaerobic respiration.  Although the mature fiber cells utilize glycolysis for cellular fuel, the 
low level of ATP production is only enough to maintain the G0 cell cycle phase, or essentially 
senescence.  Senescence seems to be required to allow the mature fiber cell to function properly 
and remain transparent.  The transition between lens epithelial to fiber cell differentiation is 
marked by changes in protein expression and protein modification as well as phenotypic changes 
such as elongation and reorganization of gap junction plaques (82). 
In the outer epithelial cells, where cell division and elongation occur, Cx43 is 
preferentially expressed along with other transporting proteins, for example, the Na
+
 K
+
 pump, 
aquaporin 1, volume regulatory transporters, K
+
 Cl
-
 co-transporter, stretch-activated cation 
channel, GLUT1 glucose transporter, and the Na
+
 Ca
2+
 exchanger.  pH is regulated by the Na
+
 
H
+
 exchanger and the Cl
-
 HCO3
-
 exchangers.  Many animals with knockouts of these various 
channels still maintain clarity or size of the lens despite having specific channel function defects.  
However, knockouts of the lens connexins exhibit lens defects.  Although the Cx43
-/-
 mouse 
model is lethal at birth, the lenses and various other primary tissues and cells have been studied 
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to see the effect that loss of Cx43 has on the tissues that express it.  Cx43
-/-
 mice do not live 
beyond birth due to severe heart defects. However, their lenses appear normal.  In the lens, the 
most notable difference in function was a lack of proper epithelial adhesion and communication, 
because there were gaps and vacuoles present in histological samples of the knockout lenses 
(82).  The other lens connexins, Cx46 and Cx50, cause remarkable cellular changes in the lens 
when their functions are perturbed. 
 
 
Figure 1.5 A Schematic of the Vertebrate Lens and Connexin Expression Profile 
Connexins are expressed throughout the lens.  Cx43 is expressed predominately in the outer epithelial layer where 
the majority of the lens metabolism occurs.  It is also the region that has the most access to oxygen.  As the epithelial 
cells migrate around the lens to the equator, they begin to differentiate and express different proteins like crystallins, 
Cx46, and Cx50.  Cx43 expression decreases with differentiation and stops all together when fibers being to 
elongate.  Cx46 and Cx50 are required to maintain lens transparency and homeostasis.  The hypoxic nucleus is 
devoid of organelles, protein turnover and nuclei.  Original figure published in Das et al., Curr Eye Res. 2011 Jul; 
36(7):620-31. 
 
Cx46 is expressed early in lens fiber cell development and is strongly expressed and 
maintained in the mature fiber cells of the lens nucleus.  Cx46 expression begins to appear as the 
transition between outer differentiating and inner differentiating cells begins and continues into 
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the nucleus.  In the same region where Cx46 is being up-regulated and Cx43 is down-regulated, 
the lens becomes hypoxic.  Oxygen tensions in this region are 5% (~40 mm Hg) at the lens 
surface to less than 1% (~8 mm Hg) oxygen in the lens nucleus.  The high metabolic oxygen 
demand in the lens nucleus is thought to be responsible for the lack of oxidative damage to lens 
core proteins since the majority of available oxygen in the lens nucleus is used for energy 
production (82).  Cx46 is not expressed in the epithelium but forms heterotypic gap junctions 
with both Cx43 and Cx50 between epithelial cells and differentiating fiber cells. Cx50 does not 
interact with Cx43 in a heterotypic manner (34, 67, 69, 82, 83).  Cx46
-/-
 mice display severe 
punctate cataract formation early in life, bone development retardation, and general bone 
malformations (74, 75).  Various mutations within the Cx46 genes of clinical patients have been 
directly linked to the cause of congenital cataracts but bone has not been analyzed in any clinical 
patients to date (62, 84-86). 
Cx50 also affects lens clarity and regulates lens differentiation, growth, and size.  Cx50 is 
expressed throughout the lens in each cell type and confers cell growth regulation qualities (82, 
87).  It was observed that Cx50
-/-
 mice possessed a smaller lens with fewer cells, but the cells 
were larger than wild type mice lens cells.  Cx50
-/-
 mice also had nuclear cataract formation, 
albeit generally less severe than Cx46
-/-
 mice (87).  The growth properties conferred to fiber cells 
from Cx50 was highlighted in a study about connexin function using mouse knock-in models 
(69, 82, 88).   
Although gene transcription and protein translation rates decline as the lens cells mature, 
Cx46 and Cx50 remain as functional membrane channels well into the mature region of the lens.  
Cleavage of connexins in the lens probably lead to stability of the functional, pH, and Ca
2+
-gated 
channel functions of Cx46 and Cx50 (61).  This would allow for the junctions to remain at the 
plasma membrane, unaffected by global protein changes in the cytoplasm since the carboxy-
terminal domains are clipped, unable to provide scaffolding functions (89, 90) and would not 
sense molecular signals related to degradation (82, 91).   
Major intracellular degradation occurs in the same differentiating fiber cells as the 
disappearance of Cx43, appearance of Cx46, and stabilization of gap junction plaques by 
carboxy-terminal domain clipping.  Evidence suggests that the creation of the organelle-free 
zone in the mature fiber cells relies on the same cellular pathways that are involved in apoptosis.  
These pathways lead to nuclear disorganization, organelle dismantling, and cellular scaffold 
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destruction.  Interestingly, with the maturation of the lens fiber cells, the lens becomes 
increasingly hypoxic, metabolism changes to favor the anaerobic type, and all organelles and 
advanced cellular structures are degraded with the exception of cytoskeletal components, the 
crystallins, and gap junction plaques (64, 67, 82, 91-93).  Similar clipping of connexins has been 
noted in cardiac tissue, where constant electrical coupling is crucial and CT domain clipping 
concurs with gap junction plaque remodeling (63, 94, 95).   
Indeed, some apoptotic proteins are used in lens cell fiber differentiation as shown by 
Weber and Menko (91, 96).  The authors showed that there is a delicate balance between 
apoptosis and defined organelle destruction that is regulated by the Bcl family of proteins and 
cytochrome c release from the mitochondria (96), indicating that fiber cell differentiation in the 
absence of sufficient oxygen is basically selective and controlled cellular apoptosis, as only 
incomplete destruction of organelles in the lens nucleus leads to cataract (91).  The authors 
termed this type of controlled-apoptotic differentiation as apoptosis-related Bcl-2- and caspase-
dependent (ABC) differentiation (96).  Similar differentiation processes take place in a few 
different cell types, such as in keratinocytes and erythroid cell differentiation, and monocyte 
differentiation into macrophages (91).  What effect connexins have on this differentiation 
pathway is unknown at this time.  It could be hypothesized that in the lens, Cx50 must maintain 
heterotypic gap junctions with Cx46 in order for differentiation and growth to occur, because 
only Cx50
-/-
 mice display reduced fiber cell differentiation and growth, and Cx43 and Cx50 do 
not form heterotypic junctions (as discussed above).  Functional channels formed by Cx46 and 
Cx50 could pass selective molecules needed to drive organelle destruction or maintain cellular 
homeostasis during differentiation.  Another hypothesis could be that Cx50 homotypic or Cx46 
heterotypic junctions are necessary for correct cytoskeletal maintenance due to their protein 
scaffolding abilities.  Many questions remain regarding lens cell differentiation as a whole. 
Work by Mathias, Gong, and White showed that only Cx46 is responsible for gap 
junction coupling in the mature fibers, and that since the CT domains of both connexins are 
clipped rendering Cx50 nonfunctional, it is Cx46 that supplies the much needed metabolite and 
waste circulation to the lens nucleus in conjunction with high-affinity metabolite transporters 
known to be up-regulated and maintained in mature fibers (82).  By knockout analysis of Cx50
-/-
 
mice, Cx50 appears to play a role in regulating lens differentiation and growth before the CT 
domain becomes cleaved, so the functional consequence of cleaved Cx50 in the lens nucleus is 
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irrelevant to lens development at the point in which Cx46 takes on functional significance.  
However, without functional Cx46, lenses lose homeostasis and develop cataracts. A direct 
correlation has been made between lens epithelial cell differentiation and growth and presence of 
Cx50 homotypic gap junctions (82, 97, 98).  Much evidence points to connexins playing a 
central role in the development of a naturally avascular and functionally unique hypoxic tissue.  
 Signals and Metabolites that Traverse Connexin Channels 
The abundance of cellular second messengers and ions and the number of connexins 
expressed in each tissue makes the possible gap junction selectivities almost limitless. A few 
important metabolites and signaling molecules are known to traverse connexin channels, such as 
bicarbonate, Mg
2+
, Na
+
, K
+
, Ca
2+
, second messengers such as IP3, ATP, AMP, cAMP and cGMP, 
and small metabolites including glucose and glutamate (38, 47, 78, 99, 100).  Charge and size 
selectivity of the pore depends on the type of connexins that constitute the connexon, but in 
general the pores are believed to be at least 12 Å in diameter (99). For example, homomeric 
Cx45 has a pore diameter that only allows molecules smaller than 0.3 kDa to pass, compared to 
homomeric Cx43 channels that can pass molecules up to 1.2 kDa in size (74).  The diameter of 
channels of homomeric Cx46 has not been measured.  Given the varying roles that connexins 
play in physiology, it is easy to speculate that the mixing of connexins gives distinctive 
juxtacrine channels that spread process-specific molecules, and that this spreading of molecules 
can dictate cellular responses in other nearby cells, possibly at the sub-organ/tissue level. 
There have been attempts to decipher which connexins can create heteromeric connexons 
and/or heterotypic gap junctions. Such studies are facilitated by the use of connexin chimeras 
(29, 30, 38, 99).  These chimeras often contain individual domain replacements, offering insights 
into the importance of each domain in the overall connexin gap junction function.  The charged 
residues of the extracellular loops and various residues in TM3 seem most important in Cx43 
connexon mixing and gap junction formation (44, 52).  Cx43 connexons are less selective than 
Cx26 or Cx40, and this allows for higher cAMP flux between coupled N2A and HeLa cells 
(100).  By using a molecular simulation and analysis of limited, but available, connexin 
structural data, Maeda and Tsukihara (38) observed that as a consequence of the biochemical and 
mutagenic techniques used to confer connexin gap junction transport ability, the techniques 
themselves induced structural changes in the extracellular loops and TM helices, such that the 
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disulfide bridges that stabilize the docking face could not form correctly.  This ultimately led to 
discrepancies in published data and confusion as to which connexins actually connected and 
retained selective gap junction permeability.  Therefore, the questions regarding the types of 
solutes that can pass through the various mixings of gap junctions in vivo in tissue or in vitro in 
cell cultures in any physiological state still remain controversial and unresolved. 
As outlined above, the connexin protein family is diverse, redundant, but specialized.  
Important and detailed roles of each connexin are being uncovered. However specific attributes 
are likely to be cell type and tissue type dependent.  This thesis identifies and confirms an 
additional non-channel function of Cx46 in diseased tissue similar to the hypoxic lens. Results 
suggest that Cx46 provides functional protection from hypoxia. 
 Ischemia, Hypoxia and Effects Thereof 
Cellular processes, such as differentiation, regulation of metabolism, and proliferation, 
result from the presence or absence of cellular oxygen.  The most amount of cellular energy 
created in metazoans is through oxidative phosphorylation.  When oxygen becomes limited, 
metazoans have a secondary, less efficient glycolytic energy production system, which meets the 
minimum requirement for cellular fuel and metabolites.  Glycolysis is efficient and has been 
used in some form since the beginning of unicellular life (6).  It is no surprise that glycolysis has 
survived through evolution of life to present day organisms (101).   
Ischemia, a less than adequate delivery of oxygen and nutrients to tissues, contributes to 
major medical problems in human health and disease.  Ischemic events occur during stroke, heart 
disease and infarction, diabetes, lung diseases, vascular diseases, solid tumor growth, and high 
altitude.  In each of these health states, hypoxia, or low oxygen, is common to all diseased or 
affected tissues.  Hypoxia, however, is also a fundamental physiological stimulus that takes place 
during development and tissue growth in vertebrates.  Lack of an adequate cellular oxygen 
supply, defined as hypoxia, creates a demand that far exceeds the availability of oxygen for 
oxidative phosphorylation to be efficient.  Cells begin to sense this change in oxygen and other 
environmental clues such as the buildup of metabolic waste and the increased demand for 
cellular fuel (102, 103).   
The lack of oxygen and the buildup of waste, in turn, up-regulate some response genes 
needed to correct the dire situation, such as transporters, proteolytic enzymes, and kinases, such 
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as in the case of PC12 cells (adrenal neuron pheochromocytoma) in response to treatment with 
hypoxia plus high extracellular calcium (104).  Other examples of the effects of hypoxia are 
cellular apoptosis and necrosis, as a result of irreversible metabolic changes within the cell.  The 
change in availability of cellular oxygen is sensed by a redundant system of oxygen-dependent 
hydroxylating enzymes and associated transcription factors that comprise the hypoxia-inducible 
factor (HIF) response to hypoxia in all cell types.  Much is known about this pathway (Figure 
1.6) and is reviewed below. 
 Hypoxia Inducible Factors Regulate the Cellular Hypoxic Response 
The HIF system comprises a core set of transcription factors and the proteins that 
modulate their activity.  The master regulator protein of the HIF system is a heterodimeric 
transcription factor named hypoxia-inducible factor 1 (HIF1), with both α and β monomers being 
constitutively expressed in most cell types.  There are two other known human homologs of HIF-
1α, named HIF-2α and HIF-3α.  These transcription factors are all modulated in much the same 
manner.  HIF alphas are regulated by the cellular ubiquitin-proteasome system, which follows 
the ubiquitination pathway. 
The von Hippel-Lindau protein (VHL) is the dihydroxy-HIF recognition protein subunit 
of an E3 ubiquitin ligase.   For VHL to identify and bind to HIF, an iron, oxygen, and TCA cycle 
metabolite-dependent hydroxylation reaction must occur on HIF.  The prolyl-4-hydroxylase 
domain (PHD) enzymes facilitate two oxygen-dependent reactions with one molecule of oxygen; 
one reaction involves the transfer of one oxygen atom to regulatory prolines of HIF (P402 and 
P564 on human 1α and similar in 2α/3α) (105), and the other atom to split α-ketoglutarate to 
succinate and carbon dioxide (101, 106) (Figure 1.6).  Once HIF is hydroxylated on both 
regulatory prolines, VHL recognizes and binds to it, facilitating the transfer of ubiquitin chains 
and ultimately destruction by the proteasome under normal oxygen concentrations. The Km 
values for the family of oxygen-dependent PHDs are near 100 µM, well above the cellular 
concentrations of physiological oxygen (4-40 µM or 3-6% or ~25 mm Hg), indicating the 
sensitivity and efficiency of catalysis utilizing cellular oxygen tension as a sensor (106). 
A second and equally important mode of HIFα subunit regulation is through the iron and 
oxygen-dependent hydroxylation of asparagine-803 in the carboxy-terminal trans-activating 
domain (CTD) of alpha subunits, catalyzed by the protein FIH (factor inhibiting HIF-1) (105) as 
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shown in Figure 1.6.  In the absence of molecular oxygen such as during hypoxia or in the 
presence of divalent metal chelators or competing divalent metals, the hydroxylation reactions 
cannot continue, which results in VHL not being able to bind HIF, leading to cytoplasmic 
accumulation of the alpha subunit.  Accordingly, if FIH cannot hydroxylate the HIF CTD, 
transactivation of response genes can be induced more efficiently. These two hydroxylating 
mechanisms offer a graded response to oxygen and necessary cellular metabolites and cofactors, 
which surely provide a delicate balance between metabolism and cellular health under various 
oxygen tensions (101, 105-107).  The HIF-1β subunit, also known as aryl hydrocarbon receptor 
nuclear translocator (ARNT), is constitutively expressed and not regulated by oxygen or 
metabolites, leading to dimerization of the alpha and beta subunits and translocation to the 
nucleus (105, 106). 
HIFs dimerize by utilizing their PAS and bHLH protein domains on the alpha and beta 
monomers, respectively, while leaving the amino-terminus of each monomer available for DNA 
binding and the carboxy-terminus of the alpha monomer for binding to the transactivation 
coactivator protein p300/CBP.  The HIF alpha/beta heterodimer binds to and activates DNA 
transcription at defined sites of 5’-XRCGTG-3’ where R is a purine (A or G, in sequence terms) 
and X is any purine or pyrimidine.  The alpha subunit binds 5’-XRC-3’, while the beta subunits 
bind 5’-GTG-3’ (101, 103, 105, 108) (Figure 1.6).  HIF is considered the master regulator of 
hypoxia response genes and is necessary for correct embryonic development as well as recovery 
from anemia and growth of new tissue (101, 109, 110). 
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Figure 1.6 Schematic of HIF-Mediated Oxygen Sensing 
HIF-1α and the HIF-β subunits are constitutively expressed under normal physiological conditions.  Under normal 
tissues oxygen tension conditions, the alpha subunit is degraded very rapidly upon its expression via specialized 
oxygen and α-ketoglutarate intermediate-regulated iron-dependent hydroxylases.  Enzymatic hydroxylation of 
specific proline and arginine residues by the oxygen-regulated hydroxylases provides a binding platform for the von 
Hippel-Lindau tumor suppressor E3 ubiquitin ligase (VHL).  When oxygen tension is sufficient, HIF-1α is degraded 
via the proteasome very efficiently.  Insufficient oxygen, iron, or α-ketoglutarate leads to HIF-1α stabilization and 
dimerization with the β subunit.  This leads to nuclear import and gene transcription of proteins with hypoxia 
sensitive promoters.  Prolonged hypoxia results in accumulation of HIF in the nucleus leading to transcription from 
gene promoters which contain non-standard hypoxia response elements, like connexin 46.  Permission to modify and 
reprint obtained from Oxford Journals.  Original figure: Cardiovasc Res 2006; 71:642-651. © Oxford University 
Press 
 Cellular Changes Common to Hypoxic Insults 
To date, there are at least 70 confirmed HIF gene targets in the human genome.  Each of 
these genes plays a role as part of two well defined categories of functions: 1) to increase the flux 
of catabolic, energy-rich metabolites to be used in ATP production, and for reducing molecule 
generation, and 2) to increase tissue oxygen penetrance and delivery (105).  Fandrey, Gorr, and 
Gossmann (105) offer an interesting perspective on cell specific differences. They postulate that, 
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since a graded response to oxygen is sensed the same in all cells, it is the shear amount of 
hydroxylating enzymes produced by the cell under hypoxic stresses that dictates cell type 
specific differences in the overall response.  This is logical, because some cells that operate 
better under low oxygen tensions, such as bone chondrocytes, differentiating neural crest cells, or 
differentiating fiber lens cells, respond to hypoxia differently than cells that respond transiently 
or do not respond at all, e.g. erythropoietin secreting kidney cells or cardiac and vascular tissue.  
This also dictates which proteins are up- and down-regulated during hypoxia and the sensitivity 
of gene regulation in these cells.   
All cells need to be characterized more extensively under hypoxic growth conditions to 
be able to assign proteins a specific function during hypoxia.  Since cells that are destined to 
function normally under hypoxic conditions express cell type specific maintenance proteins to 
cope with the inefficient metabolic respiration and toxic metabolic waste accumulation, functions 
assigned to proteins have the possibility of possessing other functions in a different cell type 
under different conditions.   For example, adipose tissue was found to up-regulate some 3000 
genes during mouse studies of sleep apnea, a condition where transient decreases in global 
oxygen supply occur during sleep (111).  This is in stark contrast to the known 70 genes that are 
regulated by HIF directly as mentioned above.  One obvious question raised about this 
discrepancy is what function these other 2900+ gene products have in relation to hypoxia?  
Another question that could be raised is how much HIF transcription factor is needed to 
transcribe from non-canonical HREs in promoters?  Other studies have implicated that adipose 
cells that rely on hypoxia to maintain function respond to outside stimuli differently that what 
would be expected, indicating that adipose tissue is unique because it requires hypoxia to be 
resistant to inflammatory signals (112).  Nonetheless, cells from different tissues with different 
functions respond differently to a lack of metabolic oxygen. 
The mitochondria rely on NADH and FADH2 as electron energy shuttles from the 
tricarboxylic acid cycle (TAC), and also rely on O2 as the final proton acceptor in the efficient 
production of H
+
 gradients and ATP (101).  As the amount of available metabolic oxygen 
decreases, the TAC continues to provide the reducing equivalents needed for electron transport.   
Subsequently, as time without oxygen progresses, unpaired electrons accumulate and escape the 
electron transport chain, ultimately becoming reactive oxygen species (ROS) like oxide anions 
(e.g. ·O2
-
) and peroxides (e.g. H2O2).  At the same time ROS production is increasing, HIF 
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activity is increasing which leads to controlling the expression of TAC enzyme isoforms and 
glycolytic enzymes that modulate the flux and metabolism of necessary metabolites needed for 
anaerobic respiration (113, 114).  Additionally, cells that must respond to prolonged hypoxia 
induce mitochondrial autophagy as a means of protection against damage by reactive oxygen 
species (ROS) (115). This is manifested in the hypoxic differentiating lens cells in which the 
creation of the organelle-free zone that maintains lens clarity is concurrent with increasing and 
prolonged hypoxia, as described above. 
ROS are very damaging to the cell because of their inherent high reactivity and 
ambiguous substrate preferences.  The lipids, nucleic acids, and proteins that comprise the cell 
can become extremely damaged by ROS which results in the death of the cell through either 
apoptosis or necrosis.  Thus, it is important for cells to cope with ROS stresses that are above the 
normal physiological levels produced from the electron transport chain.  Cells have a number of 
options to cope with this stress encoded in the genome and through the availability of 
antioxidants.  Enzymes like superoxide dismutase and antioxidants like glutathione can be 
produced in cells in response to ROS.  Cells can also express transporter proteins and gap 
junctions to increase the intracellular availability of antioxidants (a shared metabolite process) or 
to decrease the intracellular damage (as a dilution process) as well as express different 
mitochondrial proteins that increase the efficiency of electron transport under hypoxia (an 
induced process) (116, 117).  ROS production is not the only damaging process that occurs 
during cellular hypoxia as changes in intracellular pH play a particular role in regulating the cells 
response to hypoxia.  The pH regulation of gap junctions in particular, was described above. 
 Prolonged Cellular Adaptation Strategies to Hypoxia in the Solid Tumor and Lens 
Otto Warburg first noted that an increase in glycolysis was associated with solid tumor 
growth and termed this metabolism “aerobic glycolysis” which in present day is referred to as 
Warburg metabolism (114).  Increased and prolonged glycolytic activity is associated with 
cancer progression and clinical tests of cancer use this phenomenon to diagnose solid tumors by 
using fluorodeoxyglucose and PET imaging techniques (114, 118).  Changes in metabolic 
activity, as described above, occur chronically in many cancer cell types.  Specific changes in 
cell behavior have been attributed to the type of HIFs that are expressed during that change.  
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HIFs have been implicated as being both a cause and a marker of the aggressive solid tumor 
phenotype (106, 119) and are discussed below. 
HIF1 is generally described as the master regulator of the normal hypoxic response and in 
neonatal development, whereas HIF2 appears to be active in the prolonged hypoxic response 
such as in disease and tumors (114, 118-123).  When HIF-1α escapes the ubiquitination process 
and subsequently forms functional HIF1, it translocates to the nucleus where it binds hypoxia 
response elements (HREs) and activates transcription of target genes.  Transactivation of 
CBP/p300 occurs prior to efficient gene transcription through the carboxy-terminal 
transactivation domain (CTD) of HIF-1α and -2α. Interestingly, HIF-3α does not contain this 
transactivation domain and may serve as a transcriptional repressor of HRE responsive genes 
(120).  Unfortunately, HIF3 and the HIF-3α gene locus, in particular, has not been well studied, 
but evidence indicates that it does act as negative transcriptional regulator having negative 
impact on hypoxic renal cell growth, proliferation, stem cell development, and in inhibition of 
corneal neovascularization (120, 124-126). 
HIF2 is increasingly found to be linked to hypoxic tumor progression.  Semenza (101) 
and Kaelin (106) in their literature reviews, observed that many cellular growth and proliferation 
pathways, such as Myc, Ras, AKT/PKB, mTOR/ PI3K, and Notch, are up-regulated as a result of 
solid tumorigenesis.  Additionally, support for growth pathway up-regulation is garnered from 
studies of v-SRC and various oncogenic viruses, which when introduced into cells in culture lead 
to the up-regulation of HIF and the overall growth response.  HIF1 and HIF2 have been shown to 
functionally interact with Myc at the promoter level, indicating that HIF2 has the ability to both 
repress expression of Myc-activated genes and activate the expression of Myc-repressed genes 
through replacement of HIF1-Myc, or creation of HIF2-Myc transcriptional complexes (118). 
 Model Systems Used for the Study of Hypoxic Effects of Connexin 46  
– The Lens and the Solid Tumor 
 Lens as a Physiological Model for Cellular Hypoxic Response 
The lens is an ideal model for hypoxia due to persistent oxygen deprivation, limited 
cellular apoptotic differentiation pathway, and the cellular adaptation to nutrient deprivation and 
low intracellular pH (82, 91).  As mentioned above, the lens naturally expresses three distinct 
connexin proteins, Cx43, Cx46, and Cx50.  Each of these connexins has been ascribed functions 
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within the lens.  Cx43 provides a means of circulation through the growing and dividing 
epithelia.  Cx50 regulates the size and volume of lenses throughout development.  Cx46 provides 
the main circulatory function of antioxidants and metabolites throughout the developing and in 
particular the mature lens fibers.  Knockout of Cx50 results in low growth and maturation 
potential of the lens and contributes to cataract formation.  Cx46 knockout produces severe 
cataracts because of lens protein modifications like oxidation, truncation, and insolubility.  Since 
each connexin has a known function in the lens, one can use the lens to tease out effects in 
connexin expression levels and contribution to the survivability of the lens tissue, especially as 
this relates to hypoxia. 
Connexin 46 seems to be important for the correct function of other lens proteins under 
physiologically stressful growth conditions.  The lens is quite hypoxic in nature and when Cx46 
function is disrupted, the effects of hypoxia can be seen as cataract formation.  Our hypothesis is 
that Cx46 is needed under hypoxic conditions to help circulate necessary metabolites, such as 
sugars, ADP/ATP, NADH/NADPH, and ions, and to provide a means to dilute the damaging 
molecules produced during hypoxic insult, such as ROS, peroxides, and reduced antioxidants. 
Interestingly, the lens displays controlled apoptosis and subsequent cellular senescence 
upon full differentiation.  The mechanisms behind the formation of the organelle free zone 
(OFZ) are unknown, but there is a causal link between the OFZ and the type of ubiquitin linkage 
seen in the lens.  Oxygen tensions correlate well with the onset and creation of the OFZ as well 
as Cx46 stabilization.  This correlation drives the reasoning that hypoxia and possibly signal 
molecule dilution through gap junctions are the initiating signal. 
 The Y79 Solid Tumor as a Model of Connexin Biology in Cancer 
The Y79 cell line was first isolated from a 2.5 year old child with a maternal family 
history of retinoblastoma (128).  Retinoblastoma as a diagnosis affects roughly 3.6 children per 
million children under the age of 15 in the United States per year alone (129).  Retinoblastoma as 
a cancer exhibits many of the same features as other solid tumors in the body.  Solid tumors 
generally have the same three physiological features of nutrient and growth factor deprivation, 
low oxygen content, and low pH due to the rapidly dividing cells and unorganized growth (130).  
New vasculature is produced once hypoxic growth conditions have been reached within the solid 
retinoblastoma tumor, typically at a size above 3.5 mm
3
 (128).   
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Vasculature is needed to provide nutrients and growth factors, maintain tissue and 
cellular pH, and to remove toxic metabolites that are produced due to the hypoxic environment 
and Warburg glycolysis (130-131).  The main functions of lens gap junctions are to circulate 
these metabolites and other molecules to the epithelia.  This function would most likely be 
present in tissues lacking sufficient vasculature. 
The retina is a rather complex tissue to where 10 neuronal cell types comprise the full 
tissue, each having a specific function.  The cell layers comprising the mammalian retina include 
the inner limiting membrane (Müller cells), the nerve fiber layer (axons of the ganglion cell 
nuclei), ganglion cell layer (ganglion cell bodies), inner plexiform layer (synapses between the 
bipolar cell axons and the dendrites of the ganglion and amacrine cells), inner nuclear layer 
(bipolar cell bodies), outer plexiform layer (tips of rods and cones, and the Fiber layer of Henle), 
outer nuclear layer (cell bodies of rods and cones), external limiting membrane (segmentation 
layer),  a photoreceptor layer of rods and cones, and the retinal pigment epithelium (132-134, 
Wikipedia).  Connexin expression in these tissues is difficult to assign due to species-specific 
differences present in the literature.  Five major connexins are expressed in the mature human 
retina: Cx36, Cx43, Cx45, Cx50 and Cx57/62.  Cx43 dominates the literature while few other 
studies in the retina have focused on other connexins.  Interestingly, retinoblastoma can occur 
from any of the cell types and the Y79 cell line has not been identified as originating from any 
one layer in the retina but instead in which a cell type that loses the RB protein first (134). 
 Aim of Dissertation 
The aim of this dissertation is to uncover the regulatory mechanism in which Cx46 
provides resistance to cell death caused by hypoxia and/or ischemia. 
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Chapter 2 - The Anti-Tumor In Vivo Function of Connexin 46 in a 
Human Y79 Retinoblastoma Xenograft Tumor Model 
This chapter was previously published as: 
Diana B. Burr*, Samuel A. Molina*, Debarshi Banerjee, Derek M. Low, and Dolores J. 
Takemoto. “Treatment with connexin 46 siRNA suppresses the growth of human Y79 
retinoblastoma cell xenografts in vivo” Exp Eye Res. 2011 Apr;92(4):251-9.  *Co-First Author 
 Abstract 
Tumors with a hypoxic component, including human Y79 retinoblastoma cells, express a 
specific gap junction protein, Connexin 46 (Cx46), which is usually only found in naturally 
hypoxic tissues such as the differentiated lens.  The aim of this study was to investigate if Cx46 
downregulation would suppress Y79 tumor formation in vivo.  Five-week old nude mice were 
subcutaneously implanted with human Y79 retinoblastoma cells and treated with intratumor 
siRNA injections of 30 μg Cx46 siRNA (n=6), 30 μg non-silencing siRNA (n=6), or no siRNA 
treatment (n=6) every 2 days for a maximum of 10 treatments.  Tumor volume (TV) was 
calculated from the recorded caliper measurements of length and width.  Excised tumors were 
measured and weighed. Western blot analyses were performed to evaluate Cx46 and Cx43 
expression in tumors which received Cx46 siRNA, non-silencing siRNA, or no siRNA treatment.  
Tumor histopathology was used to assess tumor features.  Cx46 siRNA treated Y79 tumors had a 
reduced TV (287 mm
3
 ± 77 mm
3
) when compared to the tumors of mice receiving the negative 
control siRNA (894 mm
3
 ± 218 mm
3
; P ≤ 0.03) or no siRNA (1068 mm3 ± 192 mm3; P ≤ 0.002). 
A 6-fold knockdown of Cx46 and a 3-fold rise in Cx43 protein expression was observed from 
western blots of tumors treated with Cx46 siRNA compared to mice treated with non-silencing 
siRNA.  Knockdown of Cx46 with siRNA had an antitumor effect on human Y79 retinoblastoma 
tumors in the nude mouse model.  The results suggest that anti-Cx46 therapy may be a potential 
target in the future treatment of retinoblastoma. 
 Introduction 
Ocular retinoblastoma is a rare, pediatric ocular tumor, caused by mutations in the 
retinoblastoma tumor suppressor gene (RB1), which may occur in both eyes of affected children. 
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Current treatment methods with chemotherapy using carboplatin, vincristine, and 
etoposide, cryotherapy, laser photocoagulation, and external beam radiation therapy have greatly 
improved patient outcome against this neoplasia without enucleation (1, 2).  However, even in 
successful cases, significant side effects have been reported, including secondary malignant 
tumor development and deformities at the irradiation site, ischemic necrosis of the optic nerve, 
ototoxicity, and bone marrow suppression with potentially subsequent systemic septicemia (3-5).  
Currently, there is a need for an initial therapy and drug development for therapies, which are 
less toxic and can be used for extended periods to prevent or suppress tumor growth and protect 
the remaining unaffected eye to prolong vision in these young children.   
The retina is usually highly oxygenated due to extensive vascularization, however, 
retinoblastoma, like many solid tumors, has a hypoxic stage where oxygen levels are 
approximately 1.5%, allowing tumor cells to have a growth advantage over normal tissue (6).  
Growth at 1% oxygen inside the early tumor is supported by the up-regulation of the regulatory 
transcription factor complex, hypoxia-inducible factor (HIF).  Many genes, often controlled by 
HIF, contribute to the maintenance of hypoxia and are involved in early tumor formation and 
progression (7).  One of these genes is the gap junction protein, connexin 46 (Cx46), which is 
naturally expressed in the hypoxic lens but can also be found in ischemic tissues such as wounds, 
infarcts, and traumatized or avascularized tissues (8).  Our lab has recently identified Cx46 
expression in solid tumors with a hypoxic component.   
Gap junctions are membrane channels that allow intercellular communication through the 
passage of small molecules, ions, and metabolites.  Connexins, the proteins that make up the gap 
junctions, are expressed in a tissue specific manner (9) and normal connexin expression is often 
altered in neoplasia.  Connexins began to be investigated as tumor suppressors when it was 
observed that Cx32 knockout mice were more likely to develop liver tumor formation in 
comparison to their wild type littermates (10). It is suspected that many tumors have a decrease 
in their normal connexin expression and may also have an impaired ability to form gap junctions 
with connexin proteins (11).  The loss of gap junction communication and gap junction proteins 
has been associated with the development of neoplastic and malignant progression (12-15). 
Several connexins have been investigated for their growth inhibitory effects, but Cx43 has the 
best documented effects as a tumor suppressor (11, 14-19).  Several tissues, such as prostate and 
breast tissues, naturally express Cx43 and it is required for normal development and function.  
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However, in both prostate and breast cancer, expression of Cx43 is significantly downregulated 
(16-17).  In the normal prostate samples, nearly all specimens were positive for Cx43, while 
nearly two thirds of prostate cancer tissues were negative for Cx43, and Cx43 was present in 
only 10% of poorly differentiated prostate tumors (16). While overexpression of Cx43 restored 
growth control in MDA-MB-435 human breast tumor cells in vitro (18), Cx43 upregulation 
suppressed tumor growth in MDA-MB-231 human breast tumors in vivo (11).  Lastly, Cx43 
knockdown with siRNA prompted development of an aggressive tumor phenotype (19). Studies 
of Cx43 with retinoblastoma protein (Rb1) also suggest that Cx43 suppresses tumor formation 
(20). 
One very important feature of tumors is their adaptation to hypoxia which then favors 
tumor growth and survival beyond that of normal tissue. We previously reported that the 
hypoxia-specific gap junction protein, Cx46, is upregulated in MCF-7 breast cancer cells and 
human breast tumors but is not found in normal breast tissue.  Downregulation of Cx46 
suppressed tumor growth in xenograft MCF-7 cell tumors (21).  We hypothesized that the 
presence of Cx46 promotes tumor growth in hypoxia.  Our lab has also shown that 
overexpression of Cx46 is sufficient to protect a gap junction deficient cell line, neuronal 2A 
cells (N2A), from hypoxia-induced cell death, while overexpression of Cx43 does not offer any 
protection compared to wild-type cells.  Furthermore, downregulation of Cx46 in lens epithelial 
cell lines, which naturally thrive in hypoxia in vitro, rendered these cells sensitive to the effects 
of hypoxia (21).   
Retinoblastoma, as well as many other tumors, has an early hypoxic growth stage, 
allowing tumor cells to have a growth advantage over normal tissues.  In human lens epithelial 
cells, a reciprocal relationship exists between the expression of the tumor suppressor, Cx43, and 
the hypoxia-specific Cx46.  The reciprocal relationship may also be present in tumors, and 
therefore, the tumor suppressor effects of Cx43 may be absent, promoting tumor growth (Burr 
DB, et al. ARVO Abstract 1575, 2010).  The purpose of this study was to determine if Cx46 is 
expressed in the human Y79 retinoblastoma cell line.  In this study, we investigate Cx46 as a 
novel gap junction protein which confers resistance and protects cells from hypoxic death.  We 
found that human Y79 retinoblastoma cells and tumors highly express Cx46 and have minimal 
expression of Cx43.  Our hypothesis is that Cx46 downregulation, using short interfering RNAs 
(siRNA), will prevent or suppress Y79 retinoblastoma tumor development in vivo. 
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 Materials and Methods 
 Cell Culture 
 Y79 cells, a human retinoblastoma cell line, were purchased from the American Type 
Culture Collection (ATCC), suspended and grown in RPMI-1640 medium (Invitrogen), 
supplemented with 20% premium fetal bovine serum (FBS) (Atlanta Biologicals), 50 U/mL of 
penicillin, 50 μg/mL streptomycin, and 50 μg/mL gentamycin (Gibco).  Neuro2A cells (N2A) 
were grown in Low Glucose DMEM (Invitrogen) supplemented with 10% premium FBS 
(Atlanta Biologicals) with 50 U/mL of penicillin, 50 μg/mL streptomycin, and 50 μg/mL 
gentamycin (all Invitrogen).  All cultures were maintained in a humidified 37ºC atmosphere of 
ambient air (21% O2) and 5% CO2.   
 Hypoxia and Cell Viability Assay 
 Hypoxia was defined as 1% O2, 5% CO2 and was maintained in a dual-controlled 
chamber (Bio-Spherix, ProOx Model C21, Redfield, NY) inserted into a temperature-controlled 
incubator, using N2 as a displacement gas, at 37ºC and 100% relative humidity.  Normoxic 
conditions were defined to be 21% O2, 5% CO2 at 37ºC with 100% relative humidity.  Y79 cells 
were suspended in RPMI-1640 media, grown in 100 mm dishes, seeded at 2.25x10
5
 cells/plate, 
and incubated for up to 7 days in normoxia (21% O2, 5% CO2) or hypoxia (1% O2, 5% CO2), 
using pre-equilibrated hypoxic media for the hypoxic studies.  Cell count and viability were 
assessed every 24 hours by removing an aliquot of the cell suspension.  Cell viability and 
number was measured by automated trypan blue staining and counting using an Auto T4 
Cellometer and associated software (Nexcelom Bioscience) set up for Y79 counting. 
For the N2A hypoxia studies, N2A cells were stably transfected with pEGFP-Cx43GFP 
or pEGFP-Cx46GFP using Fugene 6 (Roche) followed by selection for 6-8 weeks in 1000 
µg/mL G418 (Research Products International).  Stable lines were maintained in the presence of 
500 µg/mL G418.  For the hypoxia cell viability studies, N2A lines were plated at 15,000 
cells/well in an OptiLux clear bottom 96 well plate (BD Biosciences) and let attach for 6-12 
hours in normoxic culture conditions.  Media was then replaced with 100 µL antibiotic free 
growth media equilibrated to either 1% or 21% oxygen for hypoxic or normoxic assay and 
placed into the hypoxia or normoxia incubators, respectively.  At the end of the indicated 
treatment period, 20 µL of CellTiter Blue Cell Viability Assay (Promega) fluorescent substrate 
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was added per well, mixed, incubated respectively for 2 hours, and then read on a Carry Eclipse 
fluorescent plate reader using the excitation/emission wavelength (slit) settings of 560 nm 
(10)/590 nm (20) at a 400V PMT setting.  Fluorescence is directly proportional to the number of 
live cells. 
 Y79 siRNA Knockdown and Viability Studies 
 Optimization of the siRNA transfection protocol for Y79 cells was performed in vitro 
prior to the in vivo pilot/proof-of-concept study.  Cells (2.0x10
5
 Y79 cells) were plated in a total 
of 0.4 mL of complete RPMI media 16-24 hours prior to siRNA transfection and placed in 
normoxic growth conditions.  Each siRNA were mixed with various amounts of HiPerfect 
(Qiagen), according to the manufacturers suggestions in serum-free RPMI, at ratios of 1 µg 
siRNA : 3 µL HiPerfect, 1:6 and 1:12.  Various combinations were tried and the remaining 
transfections were completed using 250 nM siRNA and 15 µL of HiPerfect (as to avoid cell 
death) in a total of 100 µL mixture per well of a 12 well plate with a 20 minute incubation at 
room temperature.  Transfection mixture (0.1 mL) was added to the 0.4 mL of pre-incubated Y79 
cells, mixed, and allowed to transfect in normoxic conditions for 6 hours prior to the addition of 
0.5 mL complete RPMI equilibrated to either 21% or 1% oxygen.  For the knockdown studies, 
siRNA transfected Y79 cells (250 nM) were kept in normoxic growth conditions for a further 18, 
42 or 66 hour incubation period (to give 24, 48 or 72 hours post-transfection time points), then 
harvested and lysed according to the protocol below.  For the viability studies, siRNA transfected 
cells (250 nM) were incubated in normoxic or hypoxic conditions for a further 18, 42, or 66 
hours (to give 24, 48, and 72 hour post-transfection time points).  At the end of the incubation 
period, the cell suspension was transferred to a microcentrifuge tube and mixed 1:1 with trypan 
blue solution.  Cell viability and number was measured by automated trypan blue staining and 
counting using an Auto T4 Cellometer and associated software (Nexcelom Bioscience) set up for 
Y79 counting. 
 Transplantation of Human Y79 Retinoblastoma Cells into Nude Mice 
The study protocol and procedures were approved by the Kansas State University 
Institutional Animal Care and Use Committee.  All experiments were conducted in accordance 
with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.  The 
human Y79 retinoblastoma cell tumor nude mouse model has been previously characterized (22).  
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The human Y79 retinoblastoma cell line was suspended in Iscove’s culture medium (Invitrogen) 
supplemented with 20% FBS.  Five-week old, mixed sex, homozygous Nu/Nu nude mice (strain 
NuFoxn1) (n=18), purchased from Charles River Laboratories (Wilmington, MA), were 
subcutaneously transplanted with 1x10
7
 human Y79 retinoblastoma cells in 0.5 ml total volume 
of a 1:1 mixture of basement membrane matrix (BD Biosciences) and Iscove’s medium 
supplemented with FBS, in the left dorsal region.  Assessment of tumor development was 
performed daily.  Once a tumor was palpable, typically 3 to 7 days after cell transplantation, 
treatment was initiated via intratumor siRNA injections.  Mice were divided into 3 treatment 
groups with 6 mice in each group.  Groups received intratumor injections of 30 µg Cx46 siRNA, 
30 µg of non-silencing Allstars Negative Control siRNA, or they remained sham treated.  Anti-
Cx46 siRNA (Target sequence: CGC ATG GAA GAG AAG AAG AAA) and negative, non-
silencing siRNA (catalog #1027281) were purchased from Qiagen (Valencia, CA).  Intratumor 
siRNA treatment was given every other day for a maximum of 10 treatments.   
 Mice were examined every other day prior to siRNA treatment and the length (L) and 
width (W) of the tumors were measured with calipers to the nearest millimeter and recorded. 
Tumor volume was estimated using the following formula: TV = (LxW
2
)/2.  The tumor size 
measured immediately prior to the first siRNA injection was considered the day 0 measurement.  
Once a tumor became larger than 15 mm in any dimension or 10 siRNA treatments had been 
administered, mice were euthanized by CO2 inhalation followed by thoracotomy, as a secondary 
method.  Tumors were immediately excised, measured in 3 dimensions (mm), and weighed (mg).  
Tumors were sectioned in half, one section was snap frozen in a cryogenic vial to be 
homogenized for western blot analysis, while the remaining half was immersion-fixed in 10% 
formalin.  Formalin-fixed tumor tissues were embedded in paraffin, serially sectioned and 
processed for standard hematoxylin and eosin (H&E) staining.  Sections were pathologically 
evaluated for tumor features and cellular characteristics by a board-certified veterinary 
pathologist. 
 Western Blot 
 Cx46 and Cx43 expression were measured by Western blot analyses and were carried out 
as previously described (23).  Y79 cells and tumors were homogenized in RIPA buffer 
containing a protease and phosphatase inhibitor cocktail (Calbiochem).  Homogenates were 
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sonicated for 10 seconds on ice, three times, and then centrifuged at 2000 x g for 15 minutes at 
4ºC.  Equal amounts of protein, determined by the Bio-Rad Protein Assay, were used.  
Supernatant proteins were separated on an 8% SDS-PAGE gel and transferred to nitrocellulose 
membranes (OPTI-TRAN, Midwest Scientific).  Membranes were blocked overnight at 4ºC in 
5% nonfat powdered milk in tris-buffered saline (TBS), and then were incubated with the rabbit 
anti-Cx46 (1:1000 dilution) or rabbit anti-Cx43 (1:7500 dilution) antibodies overnight at 4ºC, 
then incubated with a goat anti-rabbit-HRP secondary antibody (1:10000 dilution, Thermo 
Scientific Pierce, 31460).  Rabbit anti-Cx46 antibody (US Biologicals, C7858-07A) and rabbit 
anti-C-terminal Cx43 antibody (Sigma-Aldrich, C6219) were commercially available.  β-actin 
(Sigma-Aldrich, A5441) and α-tubulin (Sigma-Aldrich, T6074) were used as loading controls.  
The blots were visualized using SuperSignal West Femto substrate (Pierce).  Blots were digitized 
and analyzed, using UN-SCAN-IT software (Silk Scientific).   
 Statistical Analyses 
 Commercial software (Origin; Microcal Software, Inc., Northampton, MA) was used for 
statistical analyses.  Results were expressed as the mean ± SEM and differences of P ≤ 0.05, 
using a one-way analysis of variance, were considered statistically significant.  The number of 
replicates (n) are given with each figure. 
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 Results 
 Cx46 Expression in Y79 Retinoblastoma Cells in vitro 
 
 
Figure 2.1 Y79 Cells Express Cx46 and Thrive Under Hypoxic Conditions 
(A) Y79 whole cell lysates probed with rabbit anti-Cx46 antibody and mouse anti-tubulin antibody, demonstrating 
Cx46 expression in human Y79 retinoblastoma cells when compared to control human lens epithelial cells (HLEC). 
(B) Viability of Y79 cells under normoxia (37°C humidified ambient air, 5% CO2) and hypoxia (37°C humidified 
1% oxygen displaced by N2, 5% CO2) was monitored for 7 days and recorded. (C) Total Y79 cell numbers were 
counted for 7 days under normoxic and hypoxic growth conditions. Data trends from three individual experiments 
indicate that Y79 cells express Cx46 and can survive and thrive in hypoxic conditions.  Representative experimental 
data shown. 
 
51 
To investigate the effects of Cx46 in retinoblastoma growth, we had to establish that the 
human Y79 retinoblastoma cell line demonstrated Cx46 expression.  Figure 2.1A shows that 
Cx46 protein is expressed endogenously in Y79 cells when compared to human lens epithelial 
cells (HLEC), which normally express Cx46 and naturally thrive in hypoxia.  Y79 cells were 
then grown in both normoxic and hypoxic conditions as described in the Materials and Methods 
and assessed for cell viability and growth (Figs. 2.1B and 2.1C).  Cells remained viable and grew 
in both hypoxic (5% O2) and normoxic (21% O2) growth conditions.  After 7 days in normoxic 
growth conditions, there was a 5-fold increase in the number of Y79 cells with ≥80% viability.  
In hypoxic growth conditions, there also was a 5-fold increase in the number of Y79 cells and 
with ≥80% viability after 7 days.  Similar results are presented in Figure 2.2.  In contrast, when 
N2A cells are challenged with hypoxic growth conditions, these cells do not survive past 18 
hours.  However, only N2A cells expressing the carboxy-terminal GFP tagged wild type rat 
Cx46 survive in 1% oxygen.  N2A cells expressing the related Cx43-GFP fusion protein do not 
survive hypoxia and behave similarly to un-transfected and hypoxia sensitive N2A cells (Figure 
2.3).  These data demonstrate that Cx46 confers resistance to hypoxia, and, that our hypoxia 
chamber is functional. 
 Transfection with Anti-Cx46 siRNA Negatively Affects Y79 
Hypoxic Cell Growth in vitro 
Since Y79 cells thrive in hypoxic growth conditions, we next tested if knocking down 
Cx46 expression levels affected the growth characteristics of Y79 cells.   Once knockdown 
conditions were optimized (Figure 2.4), it was clear that a high amount of siRNA was required to 
have an effect on Cx46 protein expression levels (also observed in the in vivo tumor studies).  
Y79 cells are very resistant to many transfection methods, and this high amount of siRNA may 
be necessary because of low transfection efficiency (24-26).  Next, the effects of anti-Cx46 
siRNA were assessed by western blot (Figure 2.5) and by measuring cell count and viability 
(Figure 2.6).  
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Figure 2.2  Measured Volumes (mm
3
) of Individual Xenograft Tumors Used in this Study 
Y79 cells exhibit normal growth characteristics in 1% oxygen. 3x10
5
 Y79 cells were placed in pre-equilibrated 
normoxic or hypoxic media (100mm dish) and incubated for up to 5 days in normoxia (37°C humidified 21% O2, 
5% CO2) or hypoxia (37°C humidified 1% O2, 5% CO2, displaced with N2). Cells grew after a 2 day lag period 
while maintaining viability under hypoxic growth conditions, indicating that Y79 cells can thrive in a hypoxic 
environment. 
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Figure 2.3 Y79 Cells Exhibit Normal Growth Characteristics in 1% Oxygen 
3x10
5
 Y79 cells were placed in pre-equilibrated normoxic or hypoxic media (100 mm dish) and incubated for up to 
5 days in normoxia (37°C humidified 21% O2, 5% CO2) or hypoxia (37°C humidified 1% O2, 5% CO2, displaced 
with N2). Cells grew after a 2 day lag period while maintaining viability under hypoxic growth conditions, 
indicating that Y79 cells can thrive in a hypoxic environment. 
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Figure 2.4 Optimization of siRNA-Mediated Knockdown of Cx46 in Y79 Cells 
Optimization of anti-Cx46  iRNA transfection in Y79 cells. (A) Initial studies of 10, 100 or 250 nM siRNA with 
ug:uL HiPerfect ratios given. Negative control (Neg) at 100 nM, ratio of 1ug siRNA:6 uL HiPerfect. (B) Secondary 
optimization of siRNA transfection using nM siRNA:uL HiPerfect ratios, as given. A ratio of 250 nM siRNA:15 uL 
of HiPerfect used for the remaining in vitro siRNA assays. (C) 30 ug/lane of ARPE-19 and Y79 whole cell lysates 
used as Cx46 immunoblotting positive controls. 
 
 
Figure 2.5 Western Blot of siRNA Knockdown in Y79 Cells in vitro 
Y79 cells treated with 250 nM and 15 uL HiPerfect for each siRNA show were grown in normoxic conditions, lysed 
at the timepoints shown and western blotted for Cx46 expression. Optimal knockdown of Cx46 was shown at 24 
hours. 
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Western blotting of Y79 cells transiently transfected with anti-Cx46 siRNA (Fig. 2.5) 
revealed that maximal Cx46 knockdown occurred at 24 hours post-transfection and rebounded at 
48 and 72 hours.  It is difficult to draw solid conclusions from the western blots based on the fact 
that the Y79 cell line is hard to transfect with any amount of siRNA.  Increasing the HiPerfect 
transfection reagent increases cell death and using other lipid-based compounds did not yield 
better results (data not shown).  Other researchers have used viral transfection to achieve a high 
level of transfection in Y79 cells (26).  Y79 cells transfected with the negative control siRNA 
showed no discernible negative effects from the transfection in both normoxic (Figures 2.6A and 
2.6C) and hypoxic (Figures 2.6B and 2.6D) growth conditions over 72 hours; viability remained 
high and cell counts increased.  Cells transfected with anti-Cx46 siRNA showed no discernible 
effects in normoxia compared to the negative control in both viability and cell count (Figures 
2.6A, 2.6C). However, when subjected to hypoxia, viability (Figure 2.6B) dropped slightly at 24 
hours, recovered at 48 hours, but remained lower than the control at 72 hours.  Y79 cell number 
in cells treated with anti-Cx46 siRNA did not increase significantly at any of the time points 
tested, while cell number greatly increased at 72 hr in the negative siRNA treated cells.  Taken 
together with the western blot data, the knockdown of Cx46 levels did cause a decrease in Y79 
cell count at 72 hr after siRNA transfection.  However, this was much less than that observed in 
the normal N2A cells.  This may suggest that knock down of Cx46 has additional effects for its 
anti-tumor activity. This could be through an increase in Cx43 once the Cx46 is decreased (see 
below). 
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Figure 2.6  Effects of Anti-Cx46 siRNA Treatment on Y79 Cell Viability and Proliferation Under 20% and 
5% Oxygen 
Viability assay of siRNA knockdown in Y79 cells in vitro. Y79 cells treated with 250 nM and 15 µL HiPerfect for 
each siRNA were subjected to normoxic and hypoxic growth conditions as shown. Viability (A, B) was measured 
and cell counts (C, D) taken to assess the knockdown effect of Cx46 on Y79 cell growth characteristics. Each data 
point shown with standard error (n = 4). 
 
 in vivo Proof-of-Concept and Dosage Pilot Study 
 
 An initial proof-of-concept and dosage study was performed prior to performing a 
statistically correct in vivo study.  Knowing that a high amount of siRNA was required for Cx46 
knockdown in Y79 cells in vitro, and using previous knowledge from a related study (21), four 
treatment groups of two mice each were used to determine the best in vivo dosage amount.  
Three dosages of 7.5 µg, 15 µg, and 30 µg/injection of the anti-Cx46 siRNA and a single dosage 
of 7.5 µg/injection of negative control siRNA were tested.  Figure 2.7 shows the effects of each 
dosage on the Y79 tumors in mice confirmed to have a tumor and Table 2.1 shows the individual 
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tumor data compiled from the study. The 7.5 µg and 15 µg/injection of anti-Cx46 siRNA had no 
effect on the growth of the Y79 xenografts, while the highest dose of 30 µg/injection showed a 
reduction in tumor growth and burden (Fig. 2.7).  Statistical analysis of this initial study was not 
performed as it was a pilot study.  For the primary in vivo study, 30 µg/injection of anti-Cx46 
siRNA was chosen for the dosage amount.   
 
 
 
 
Figure 2.7 Results of Anti-Cx46 siRNA Dosing and Proof-of-Concept in vivo Study 
Four groups of mice (n = 2) were used in the study to assess the most effective dosing regimen for the primary 
study. Tumors receiving anti-Cx46 siRNA were allowed to grow until they became a health concern for the mice 
harboring the tumors, then the mice were euthanized to prevent any further suffering. A dosage of 30 µg/Injection 
every other day was used for the primary study. Tabulated data for each mouse can be found in Table 2.1. 
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Table 2.1 Calculated Volumes (mm
3
) of Individual Xenograft Tumors Used in this Study 
Tumor volumes for individual tumors were measured and recorded on each injection day, then calculated using TV 
= [L*(W
2
)]/2. NT = Measurement not taken for that day; E = Euthanized; (Strikethrough) indicates which tumors 
were not included in the volume calculations and statistics due to being an outlier; (*) indicates which tumors were 
used in western blotting experiments. 
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 Cx46 siRNA Suppresses Y79 Tumor Growth in vivo 
The effects of Cx46 gene silencing was investigated on xenograft Y79 cell tumors in 
vivo.  All experimental and control mice developed tumors at the site of injection.  The gross 
appearance of mice 14 days post-Y79 cell implantation in untreated, control tumors, or following 
5 treatments with non-silencing siRNA or Cx46 siRNA, are shown, outlined with arrows, in 
Figure 2.8.  In control mice without siRNA treatment (Fig. 2.8A) and in mice in the non-
silencing siRNA treatment group (Fig. 2.8B), large, subcutaneous, and vascularized tumors were 
observed where Y79 cells had been injected in their dorsal areas.  Mice who received intratumor 
Cx46 siRNA therapy (Fig. 2.8C) had an extensive reduction in tumor size and vascularization.  
Images of representative excised tumors are shown in the Figure 2.9. 
 
 
Figure 2.8 Intratumor Cx46 siRNA Suppresses the Growth of Y79 Tumors in vivo 
Macroscopic appearance of Y79 tumors in nude mice 14 days post-transplantation of human Y79 retinoblastoma 
cells in (A) untreated control tumors, or following 5 siRNA treatments, with (B) 30 μg non-silencing siRNA or (C) 
30 μg Cx46 siRNA. Arrows outline the representative tumors in the left dorsal region of the mice. Tabulated data for 
each mouse can be found in Table 2. 
 
During the 21-day treatment period, the tumor growth rate and the final tumor volumes 
were greater in the untreated control and non-silencing siRNA treatment groups than in the mice 
treated with Cx46 siRNA (Figure 2.10).  Y79 cell tumors grew rapidly in the untreated control 
and the non-silencing siRNA treatment groups, while the rate of tumor growth was significantly 
reduced in the Cx46 siRNA treatment group (Figure 2.10A).  The reduction in tumor volumes of 
Cx46 siRNA treated mice were statistically significant (P ≤ 0.05), when compared to non-
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silencing siRNA or no siRNA treated groups.  The Cx46 siRNA group began to be statistically 
different from the non-silencing siRNA treatment group beginning 8 days after treatment was 
initiated and continued to be significant throughout the study (P ≤ 0.02).  The Cx46 siRNA 
group began to show significance on day 6 (P ≤ 0.04) and was also significant on day 8 (P ≤ 
0.02), day 14 (P ≤ 0.04), and day 16 (P ≤ 0.003) from the untreated, control group, however, 
days 10 and 12 were not as statistically significant (P ≥ 0.05).  Mice treated with intratumor 
Cx46 siRNA injections had significantly smaller final tumor volumes (287 mm3 ± 77 mm
3
) 
when compared to untreated control mice (1068 mm
3
 ± 192 mm3; P ≤ 0.002) or to mice who 
received intratumor injections of non-silencing siRNA (894 mm
3
 ± 218 mm
3
; P ≤ 0.03) (Figure 
2.10B).  Although the non-silencing siRNA group tumor volumes were lower than the untreated 
sham group, this was not statistically significant.  The tumor weights of the treatment groups 
paralleled the final tumor volumes closely (Figure 2.10C).   Mice in the Cx46 siRNA treatment 
group had significantly reduced mean final tumor weight (226 mg ± 75 mg) in comparison to 
mice treated with non-silencing siRNA (700 mg ± 218 mg; P ≤ 0.05) or the untreated control 
mice (864 mg ± 136 mg; P ≤ 0.01).  Data for all mice used in this study can be found in Table 
2.2. 
Y79 tumor homogenates were analyzed by western blot and probed with anti-Cx46 and 
anti-Cx43 antibodies using β-actin as a loading control.  Blots were digitized and analyzed as 
described in the Materials and Methods.  Not surprisingly, Cx46 expression was markedly 
decreased in tumors treated with Cx46 siRNA (Figure 2.11A), however, upregulation of Cx43 
protein was observed in a reciprocal manner (Figure 2.11B).  Both the sham untreated control 
and non-silencing siRNA treatment groups demonstrated high expression of Cx46 protein 
(Figure 2.11A) and had low Cx43 protein expression (Figure 2.11B).  A 5-fold reduction in Cx46 
and 6-fold rise in Cx43 expression were observed in mice treated with Cx46 siRNA in 
comparison to mice who received no siRNA treatment (Figure 2.12).  Similarly, mice treated 
with Cx46 siRNA had a 6-fold decrease in Cx46 and 3-fold increase in Cx43 expression 
compared to mice treated with non-silencing siRNA. The increase in the expression of the Cx43, 
a known tumor suppressor protein, may contribute significantly to the observed tumor reduction. 
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Figure 2.9 Gross Examination of Excised Y79 Xenografts 
Mice were euthanized and the tumors were immediately excised, measured in three dimensions (mm), imaged and 
then formalin fixed. Representative tumors shown are from cage 2, mouse 1 and mouse 2 (both treated with 30 
µg/mL anti-Cx46 siRNA); cage 4, mouse 2 (negative control); cage 5, mouse 2 (sham). Note the reduced amount of 
visible vascularization present in the anti-Cx46 siRNA treated tumors compared to either the sham or negative 
control tumor. 
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Figure 2.10 Tumor Volume of Cx46 siRNA, Non-Silencing siRNA, and 
No siRNA/Sham Treatment Groups in Mice Transplanted with Y79 
Cells 
Tumor volume of the transplanted mice was measured for a maximum of 21 
days, with the administration of 30 μg/Injection Cx46 siRNA (n = 6), 30 
μg/Injection non-silencing siRNA (n = 6), or no treatment (n = 6). (A) The 
calculated tumor volumes were averaged by treatment group and day over 
the course of the study (mean ± SE). The tumor volumes of Cx46 siRNA 
treated mice (n = 6) were statistically significant (* = P ≤ 0.05), when 
compared to non-silencing siRNA treatment group (n = 6) beginning on 8 
days after treatment was initiated and continued to be significant throughout 
the study. The Cx46 siRNA treatment group was statistically different (P ≤ 
0.05) from the untreated, no siRNA group (n = 6) beginning on day 6 and 
was also significant on days 8, 14, and 16. (B) Final measurements were 
taken on the excised tumors and the volumes were averaged by group. 
There was a significant reduction in final tumor volume after treatment with 
Cx46 siRNA (287 mm
3
 ± 77 mm
3
, n = 5) when compared to the non-
silencing siRNA (894 mm
3
 ± 218 mm
3
, n = 5) or untreated (1068 mm
3
 ± 
192 mm
3
, n = 6) groups (P ≤ 0.03 and P ≤ 0.002, respectively). (C) Cx46 
siRNA treated mice had a decreased tumor weight. Final tumor weights of 
groups treated with Cx46 siRNA, non-silencing siRNA (negative control 
siRNA) ,or no siRNA, shown as mean tumor weight (mg) ± SE (n = 6 for 
each group). The weight of tumors treated with Cx46 siRNA (226 mg ± 75 
mg) were significantly less than the tumors of mice treated with non-
silencing siRNA (700 mg ± 218 mg, * = P ≤ 0.05) or no siRNA (864 mg ± 
136 mg, P ≤ 0.01). 
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Histopathology of the tumor sections, shown in Figure 2.13, determined that mice treated 
with Cx46 siRNA had the least number and, therefore, the least density of Y79 cells when 
compared to mice treated with non-silencing siRNA or no siRNA.  There were no differences in 
the Y79 cell density between the non-silencing siRNA treated mice and mice which received no 
siRNA treatment by observation of the stains, hematoxylin (purple, nuclei) and eosin (pink, 
cytoplasm and connective tissue) in Figure 2.13. 
 Discussion 
A connection between gap junction intercellular communication (GJIC) and control of 
cell growth was established over 40 years ago (27), which resulted in a multitude of research 
reporting a loss or diminished  ability to adjoin amongst neoplastic cells or between cancer cells 
and nearby normal cells (reviewed in 28).  The tissue specific expression of connexins was 
discovered along with the finding that re-expression of specific connexins was able to reestablish 
control of cell growth.  Additionally, recovery of GJIC alone was not always capable of 
normalizing cell growth (29).  In other cases, re-expression of connexins was enough to restore 
cell growth control without restoring GJIC (30).  It has been suggested that connexins, 
independent of GJIC, may directly control growth, possibly by altering gene expression of 
neoplastic cells (31), and a change from the normal expression of connexin proteins may allow 
tumor progression.  Gap junction proteins are, therefore, often termed tumor suppressors and are 
downregulated in tumor development and progression.  
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Figure 2.11 Decreased Expression of Cx46 with a Reciprocal Increase in Cx43 Protein Expression in Y79 
Tumors of Mice treated with Cx46 siRNA 
Conversely, tumors treated with a non-silencing siRNA or were untreated showed Cx46 upregulation and Cx43 
downregulation. Equal amounts of Y79 tumor homogenate were analyzed for (A) Cx46 and (B) Cx43 where β-actin 
was used as the loading control. Lane 1: Tumor #14, sham treated tumor; Lane 2: Tumor #5, anti-Cx46 siRNA 
treated tumor; Lane 3: Tumor #11, AllStars negative control siRNA treated tumor; Lane 4: Y79 cell lysate positive 
control for Cx46 expression. Representative tumor western blots shown. 
 
However, our current work shows that upregulation of Cx46 is observed in cancerous 
cells and may help solid tumor tissues in surviving hypoxic conditions or could cause tumor 
growth through the loss of Cx43.  Human Y79 retinoblastoma cells express Cx46 and in contrast 
to connexin-deficient, wild-type neural N2A cells (Figure 2.3) Y79 cells, are able to thrive in 
hypoxic conditions over the course of several days while maintaining viability (Figure 2.2).  
Similarly, human lens epithelial cells express both Cx46 and Cx43, a related and ubiquitously 
expressed gap junction protein, but can only survive prolonged hypoxic conditions while actively 
expressing Cx46.  Gene knockdown by siRNA of Cx46, but not Cx43, makes HLECs susceptible 
to hypoxia induced cell death (21).  Although the in vitro siRNA data presented here for Y79 
cells is not completely conclusive, there is evidence that knockdown of Cx46 protein levels 
contributes to stagnated growth of Y79s in hypoxic conditions at 72 hr.   It could be inferred that 
prolonged dosing of Y79 cells with anti-Cx46 could prolong the lack of growth of Y79 cells and 
indeed this is what we show in vivo.  Further evidence of Cx46-related hypoxic growth control 
was observed from N2A cells which lack gap junctions and can be engineered to express either 
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Cx43 or Cx46.  In these cell lines, only the Cx46 expressing cells show delayed cellular death in 
1% oxygen (Figure 2.3).  Cx46 does indeed appear to play a role in cellular resistance to 
hypoxia.  Human Y79 retinoblastoma (this manuscript), human lens epithelial, rabbit lens 
epithelial, MCF-7 human breast cancer (21), and the N2A-Cx46 cell line all express Cx46 and all 
are able to survive hypoxia (Figure 2.1; Figure 2.3).  Knockdown of Cx46 in human and rabbit 
lens epithelial (21) and Y79 cell lines grown in hypoxic conditions clearly increases the negative 
effects of reduced oxygen.  
 
 
Figure 2.12 Quantitative Protein Expression Densitometry of Cx46 and Cx43 Protein Levels in 
Representative Tumors Shown in Figure 2.11 
Blots were digitized then normalized to β-actin levels and the detected protein expression of Cx46 and Cx43 in 
different treatment groups was compared, using the no siRNA treatment as a control. A 5-fold reduction in Cx46 
and 6-fold rise in Cx43 expression were observed in mice treated with Cx46 siRNA in comparison to mice who 
received no siRNA treatment. Mice treated with Cx46 siRNA had a 6-fold decrease in Cx46 and 3-fold increase in 
Cx43 expression compared to mice treated with non-silencing siRNA. 
 
Although retinoblastoma is well-known as a vascularized tumor, the early tumor is 
hypoxic and hypoxic regions exist in the advanced tumor stage (32-33).  The areas of the 
hypoxic tumor are increasingly refractory to conventional treatments, such as chemotherapy and 
radiation therapy, due to the slowly proliferating cells (32) because these therapies target rapidly 
dividing cells (33).  With the resistant nature of hypoxic tumors and the local and systemic 
complications associated with current therapy protocols, the search for drugs that are non-
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cytotoxic to normal cells and can effectively target cancer cells is continuous.  One approach 
would be to target a component of the cancerous cells which confers growth and viability of the 
tumor specifically during hypoxic events.   
We chose to evaluate in vivo treatments using a subcutaneous model as opposed to the 
eye for several reasons.  Y79 cells were used for the in vitro studies and subsequently using the 
same cell line allowed us to make direct correlations between the studies.   In a preliminary 
Fisher rat eye retinoblastoma animal model (data not presented) we intraocularly treated with 
intratumor injections and it was very difficult to inject on an every other day basis without an 
increase in eye damage due to repeated injections as well as the increased risk of death due to 
repeated general anesthesia.  The subcutaneous xenograft tumors presented in this paper were 
much easier to assess and reliably measured throughout the study which was especially helpful 
when testing an in vivo treatment protocol for the first time.  Subsequent studies are needed to 
further develop and optimize a delivery system for the siRNA drug.  Alternatively, other means 
to specifically lower Cx46 protein levels would need to be developed, such as use of a specific 
modified antibody similar to current antibody treatments for macular degeneration, or a long-
lasting siRNA derivative.  
Previously, siRNAs have been used successfully to provide a strong and specific 
knockdown of gene expression (35), and are therefore ideal for the initial testing of targets.  
Nude mice injected with Cx46 siRNA exhibited a significant reduction in Y79 cell tumor 
growth, having a greater than 3-fold decrease in mean tumor volume, 21 days after initiation of 
treatment.  Tumors treated with Cx46 siRNA had a projected knockdown of Cx46 but an 
unexpected increase in the expression of Cx43.  While untreated tumors or tumors treated with 
non-silencing siRNA had an upregulation of Cx46 and subsequent downregulation of Cx43.  
This is the first time the reciprocal relationship between Cx46, a connexin upregulated in 
hypoxia, and Cx43, a known tumor suppressor, has been reported in vivo.  Future studies would 
need to elucidate how loss of Cx46 results in upregulation of the Cx43 tumor suppressor.  These 
results demonstrate that Cx46 gene silencing using siRNA has an antitumor effect in xenograft 
human Y79 retinoblastoma cell tumors. We hypothesize that the pro-tumor effects of Cx46 may 
be partially due to its ability to confer resistance from hypoxic death to tumor cells expressing 
Cx46.  Additionally, subsequent reappearance of Cx43 may then aid cells to acquire more 
“mortal” properties and could render the tumor cells more susceptible to current antitumor 
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therapies.  However, additional studies are needed to determine the details of how Cx43 and 
Cx46 are reciprocally controlled.  Current work in our lab indicates that degradation of Cx43 is 
induced when Cx46 is expressed, and this degradation takes place in the proteasome (21).  
Additional studies on the mechanism of Cx43 reappearance upon anti-Cx46 siRNA treatment are 
outside the scope of this paper. 
 
 
Figure 2.13 Decreased Y79 Tumor Cell Burden in Mice Treated with Cx46 siRNA 
Excised tissues were fixed, embedded, sectioned and then stained with hematoxylin (purple, nuclei) and eosin (pink, 
cytoplasm and connective tissue). (A) Untreated sham Y79 tumor (cage 5, mouse 2); (B) Cx46 siRNA treated Y79 
tumor (cage 2, mouse 2); (C) Non-silencing siRNA treated Y79 tumor (cage 4, mouse 2). The representative images 
were taken by a board-certified veterinary pathologist and show the microscopic appearance of the Y79 tumors 
isolated from the xenograft mice, treated with Cx46 siRNA, a non-silencing siRNA, or sham treated for a maximum 
of 21 days. 
 
In conclusion, this study was the first to demonstrate the presence of Cx46 protein in 
human Y79 retinoblastoma cells.  This is the second neoplastic cell line and related tumor tissue 
reported to express high levels of Cx46 and reciprocally low levels of Cx43 protein.  Our 
findings reveal that local administration of anti-Cx46 siRNA can mediate effective knockdown 
of this target protein and suppress tumor growth in vivo.  We observed no associated side effects 
with siRNA treatment in our subcutaneous Y79 retinoblastoma tumor model in nude mice.  
Since Cx46 is only naturally found in the hypoxic and differentiated lens, ill effects of gene 
silencing of this protein would likely be negligible; however, a potential yet treatable side effect 
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with intraocular use may be cataract development.  While siRNAs are not an optimal treatment 
due to their short half-life and transient effects (35-36), other anti-Cx46 treatment modalities 
more suitable for therapy, such as modified RNAi or an antibody, can be developed in the future.  
The findings of this study provide an exciting new direction in drug development for the 
treatment of retinoblastoma.  In addition, Cx46 could provide an early marker for hypoxia and 
these findings could have broader significance for other hypoxia-related diseases. 
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Chapter 3 - The Promoter  
of Human Connexin 46 is Oxygen Sensitive 
Parts of this chapter have been previously published as:  
Samuel A. Molina and Dolores J. Takemoto. “The role of Connexin 46 promoter in lens 
and other hypoxic tissues” Commun Integr Biol. 2012 March/April 5(2) p114-117. 
Abstract 
Gap junctions are multimeric membrane protein channels that join the cytoplasm of one 
cell to another.  Much information about the connexins comes from electrophysiology and 
channel function studies, but relatively little information is known about non-channel functions 
of the connexins.  Lens connexins allow the movement of small metabolically relevant molecules 
and ions to pass between lens cells and disruption of this movement contributes to cataract.  
Connexin 46 (Cx46) has been extensively studied in mammalian lens, where it is found along 
with Cx43 and Cx50.  Interruption of Cx46 channel function leads to cataract formation due to 
dysregulation of lens homeostasis.  The induced loss of Cx46 suppresses tumor growth and also 
upregulates Cx43 in lens cell culture and in breast and retinoblastoma tumor xenografts.  Cx46 
influences Cx43 degradation in these models.  The upregulation of Cx46 may be due in part to 
the effects of increasing hypoxic conditions in these tissues. We report that the Cx46 promoter is 
regulated by hypoxia and that the mRNA transcript that is produced under hypoxia is similar to 
the transcribed product observed under normoxia. 
 Introduction 
There are 21 genes in the human genome that encode 20 functional connexin proteins.  
Many connexins are expressed in a tissue specific pattern while others, like connexin 43 (Cx43), 
are nearly ubiquitous.  Connexins are often co-expressed with other connexins in the same cell.  
Connexins assemble into homotypic or heterotypic hexameric assemblies termed connexons, or 
half gap junctions.  The connexins that comprise the gap junction channel influence the size and 
charge of the pore as well as the type of molecules that can traverse through it (1-4).  Proteins are 
often cell type specific and with the sheer number of possibilities of connexin gene expression in 
a given tissue, cells can fine tune the types of molecules they need by regulating connexin gene 
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expression.  However, there is little known about tissue specific connexin gene regulation.  
Literature on this topic is limited to a small set of connexin proteins known to cause disease, 
such as Cx43 in the heart, Cx50 in the lens, and Cx26 in the ear (5-7).  Data from developmental 
studies are limited as well with most analysis performed in mice for a few select connexins at a 
time. 
Although there is much information about connexin electrophysiology and channel 
function little information is known about non-channel functions of the connexins.  Studies of 
Cx46 outside of the eye are limited.  Cx46 has been extensively studied in the mammalian lens, 
where it is found with Cx43 and Cx50 (8).  These three connexins are differentially expressed in 
the various regions that define the lens.  In the outer epithelial layer, Cx43 and Cx50 are the 
predominate connexins.  Immature outer fiber cells express lower amounts of Cx43 and roughly 
the same amount of Cx50.  As the fiber cells mature, they lose the ability to maintain protein 
expression and turnover.  However, once the cells further differentiate into mature fiber cells 
they retain functional Cx46 and Cx50 gap junction channels (8-10).  Interruption of Cx46 
channel function leads to cataract formation in the lens (11-16).  Cataract is the most notable 
defect in Cx46 null mice and Cx46 is the dominant functional gap junction in the mature region 
of the lens (8, 17). 
Our lab has hypothesized that Cx46 is important for cellular survival during hypoxic 
conditions.  We subsequently showed that exogenous Cx46 prolongs survival from hypoxia-
induced cell death in mouse neuro2a (N2A) cells (18) and is expressed abnormally in solid 
tumors (18, 19).  Cx46 is upregulated by hypoxia in rabbit lens epithelial cells, which express 
Cx46 naturally (18).  We also demonstrated that Cx46 affects tumor growth in two separate 
human xenograft studies (18, 19).  In both studies, the xenograft cells were allowed to form 
sizeable solid tumors then each tumor was treated with high doses of Cx46 siRNA directly 
injected into the tumor at various positions.  We demonstrated that Cx46 was upregulated in 
early growth tumors and knockdown of Cx46 by siRNA resulted in slower growing tumors, 
either by the prevention of Cx46 upregulation or by knockdown of existing and ongoing Cx46 
mRNA expression.  The amount of Cx43 protein found in the tumor increased when Cx46 
protein decreased (19).  This finding could explain why the tumor xenografts slowed their 
growth when treated with anti-Cx46 siRNA.  Cx43 is a known tumor suppressor and a decrease 
in its expression is casually linked to tumor progression and metastasis (9, 20-23).  This 
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mechanism of tumor suppression may contribute to the slow growth of anti-Cx46 siRNA treated 
tumors. We then determined why and how Cx46 is upregulated in a tumor environment since it 
is thought to be unique to lens fiber cells. 
Lens fiber cells are differentiated via the master differentiation transcription factor PAX6 
which controls eye development and protein expression in all parts of the eye during 
development.  Other eye specific transcription factors that contribute to development include 
PAX2, MITF, FKHL7, PITX2, PITX3, HESX1, CRX, Hedgehogs, and NRL (The Online 
Metabolic and Molecular Bases of Inherited Diseases: http://dx.doi.org/10.1036/ommbid.281).  
Analysis of mutated eye development in mice has led to the identification of the majority of 
transcription factors involved in the eye development.  In particular, PAX6, CHX10, and PITX3 
are all important in lens maturation and result in ocular malformation when mutated based on 
mutational analysis in mice.  Cx46 expression is maintained in the mature regions of the lens.  
None of these transcription factors are predicted to bind to the GJA3 promoter as seen in Figure 
3.1.  
Of interest to our lab is the regulation of the lens fiber cell specific connexin 46, GJA3.  
Limited data is available for this protein in regards to overall embryonic development because it 
is thought to be a lens-only protein.  However, our lab has found Cx46 gene and protein 
expression in hypoxic tissues, therefore the regulation of Cx46 gene transcription is important to 
understand in the context of both the hypoxic lens and to understand Cx46 role in hypoxic solid 
tumors.  Other labs have seen expression of Cx46 in adult osteoblasts and osteosarcomas (24), 
and placental tissue (S.J. Lye, E. Winterhager, and  J. Fandrey. Deutsche Physiologische 
Gesellschaft 2012, Dresden, Germany). 
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Figure 3.1. Predicted Transcription Factor Binding Sites in the Human Connexin 46 Promoter as Analyzed 
with SA Biosciences TF Prediction Web Software 
Numbering is from chromosome ends.  Red arrow indicates start and direction of transcription.  Each of the 
predicted transcription factors lies within 1 kb upstream of the TSS.  This sequence was selected for analysis in this 
chapter.  Four major transcription protein families may bind to the Cx46 promoter: Early growth response (Egr), 
Myocyte enhancing factor (MEF), TATA binding protein (TBP) and Nuclear factor erythroid-derived 2 (NF-E2 or 
Nrf2).  Image output from SA Biosciences. 
 
No traditional promoter studies have been performed with the human Cx46 gene.  The 
transcriptional start site of the GJA3 gene is only predicted based upon mRNA and 5’-rapid 
amplification of cDNA ends (5’RACE) analysis studies in mouse cells and embryos.  In a study 
by Anderson et al (25), two different transcription start sites were identified, each marking the 
alternative exons 1a and 1b (Figure 3.2).  The mechanism that drives tight regulation of the 
connexins in all cell types is unknown.  GJA3 exons 1a and 1b did not contain the same 
sequences when analyzed by 5’RACE and subsequent sequence analysis.  The authors suggest 
that connexin genes are expressed by alternative promoters.  This type of regulation scheme 
would afford tight regulation of connexin genes in all cell types.  Another feature the authors 
point out is the varied use of internal ribosome entry sites (IRES) in many connexin 5’UTRs, 
including Cx26, Cx32, and Cx43 (26).  The Anderson et al. (25) work was performed with a 10-
12 day old mouse embryo cDNA library.  The connexin genes could be controlled differently 
between mouse and human cells or even between species or stages of development. 
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Figure 3.2. Mouse Cx46 mRNA is Present in the 17 Day Old Adult and the E14.5 Developing Embryo 
This RT-PCR experiment shows that various connexin transcripts are present in a variety of tissues in the young 
adult mouse.  The red box outlines the two detected forms of Cx46 mRNA using two separate PCR primer sets that 
cross exon-intron boundaries, effectively amplifying cDNA made from only mature RNA.  Taken from Anderson et 
al. Genomics. 2005 Feb;85(2):238-44. “Variable promoter usage and alternative splicing in five mouse connexin 
genes” with permission from Elsevier. 
 
Treatment with the protein kinase C activator and phorbol ester TPA induced Cx46 
expression in lens cells correlating with a reduction in Cx43 and an increase in Cx46 protein 
levels (27).  The Cx46 mRNA was most upregulated by three hours post-treatment, while the 
Cx46 protein levels increased up to six hours after treatment.  TPA administration to lens cells 
caused an increase in GJA3 mRNA, which signifies that the promoter may be regulated by trans-
acting transcription factors.  TPA also caused a delayed but significant Cx46 protein response, 
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which indicates that the newly transcribed Cx46 mRNA is most likely translated after the 
increased transcription.  By analyzing the promoter of Cx46, we seek to understand why that 
specific connexin is preferred by the cell in a given growth condition, particularly hypoxia.  In 
this chapter, the core promoter elements that allow increased transcription under hypoxic growth 
conditions were studied. 
 Materials and Methods 
 Cell Culture and Hypoxic Treatments 
Human lens epithelial cells (HLEC), mouse neuro2A (N2A), and human Y79 
retinoblastoma cells were cultured at 37°C in ambient air supplemented with 5% CO2.  HLEC 
and N2A cells were cultured in Low Glucose DMEM (Invitrogen) supplemented with 10% FBS 
(Atlanta Biologicals).  Y79 cells were cultured in RPMI-1640 (Invitrogen) supplemented with 
20% FBS.  Hypoxia (1% oxygen) was induced by use of a ProOx Hypoxia Chamber 
(BioSpherix, Ltd) using N2 as the displacement gas supplemented with 5% CO2.  The ProOx 
Chamber was temperature controlled by inserting it into a 37°C culture chamber. 
 Construction of GJA3 Promoter 
1183 bp immediately upstream of the transcription start site (TSS) was synthesized 
(GenScript, Inc) and supplied in pUC57 by flanking EcoRV restriction sites (1195 bp total 
length).  Since the GJA3 gene lies in the negative orientation, the promoter sequence was based 
upon the reverse positive strand, in other words the promoter nucleotide sequence chosen 
precedes the TSS in a 5’→3’ direction ending at the TSS.   
 Promoter-Linked Luciferase Studies 
Each promoter fragment that was tested was generated by PCR using the following 
primers:  Reverse primer prhCx46-R1PCR-BamHI 5’-
GCAGGATCCCAGTGTGCGCTGCGCCCGAC-3’; Forward primer pr46-810StuI-EcoRI 5’-
TCAGAATTCAGGCCTCGCCCTGGCATCTCG-3’; Forward primer pr46-482AvrII-EcoRI 5’-
TCAGAATTCCCTAGGTGCCCGACGCCCAC-3’; Forward primer pr46-287SphI-EcoRI 5’-
TCAGAATTCGCATGCCCCGGAGTGCGT-3’; Forward primer pr46-147BsmI-EcoRI 5’-
TCAGAATTCGAATGCGGACGCGGGCGAGT.  The full-length (1183 bp) was removed from 
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pUC57 by excision with EcoRV.  Directional cloning of each promoter construct into the 
multiple cloning site of the pMetLuc2-Reporter vector (Clontech, Inc.) was carried out with 
either EcoRV for the full-length or EcoRI/BamHI (New England Biolabs) for the shorter 
fragments.  All final reporter vectors were DNA sequenced to verify correct orientation and 
sequence. 
Control plasmids encoding either renilla or firefly luciferases under the control of either 
no or constitutive promoters were used for the normalization of data.  Control vectors were co-
transfected with each Cx46 promoter reporter vector using Fugene 6 (Roche) into white opaque 
flat bottom 96-well plates containing 20,000 cells per well, in triplicate.  For the hypoxia control 
reporter vector, pTransLucent-Hif1 plasmid (Panomics) was used; for the cell positive control 
vector, pGL4.20 (Promega) was used.  The promoter reporter negative control vector was the 
empty and promoter-less pMetLuc2-Reporter vector; the promoter reporter positive control 
vector was pMetLuc2-Control with luciferase driven by the CMV promoter. 
 5’ Rapid Amplification of cDNA Ends 
RNAs from normoxic (~21% O2) and hypoxic (1% O2) HLEC and Y79 cell cultures 
grown in T75 flasks for 7 days were harvested with the aid of the RNAeasy Mini Prep Kit 
(Qiagen) according to the manufacturer’s directions using QiaShredder cartridges (Qiagen).  All 
cells used were ≥75% viable on the day of harvest.  RNA was quantified by using a NanoDrop 
(Thermo Scientific) and the quality assessed by analysis of 28S:18S RNA bands on a 1% agarose 
tris-borate EDTA native gel electrophoresis in the presence of 0.5 µg/mL ethidium bromide with 
a 0.24-9.5 Kb RNA Ladder (Invitrogen).  Intact rRNA bands indicated intact total mRNA 
extraction. 
First-strand cDNA synthesis for 5’RACE analysis was carried out according to the 
manufacturer’s directions in the SMARTer™ RACE cDNA Amplification Kit (Clontech).  
Briefly, 2.75 µL of total mRNA (~500 ng/µL) was added to a reverse transcription reaction 
containing the 5’-CDS Primer A and the SMARTer IIA oligonucleotide (similar to an adaptor) to 
generate random 5’-IIA-adapted mRNA-based 5’RACE cDNA products.   
2.5 µL of 5’RACE ready cDNA was used as the template for the gene specific primer 
PCR step.  Reverse strand gene specific primers used in the 5’RACE analysis were as follows: 
#5 hsCx46wt_REV_NS_AgeI 5’-TCGACCGGTGATGGCCAAGTCCTCCGGTC-3’; #36 
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gja3RP1 5-‘AATTCCTTTCACACGTGCGGTGCT-3’; #38 gja3RP2 5’-
TGATCGCCATCCCTGCAGCC-3’; #42 PCx46-exon3-5 5’-
GGCTCCCGGCCGCTCTGAAAAGAATTCC-3’; #65 huCx46F2-PCR 5’-
ATGGGCGACTGGAGCTTTCTGG-3’ (from Nielsen et al. 14 (6): 2470. 2003); #66 
huCx46R2-PCR 5’-CTAGATGGCCAAGTCCTCCGGTCTGGC-3’ (from Nielsen et al. 14 (6): 
2470. 2003).  Ten µM of each reverse gene specific primer and 1x Universal Primer Mix were 
used to generate the 5’RACE gene specific products by three-step PCR using Phusion GC 2X 
Master Mix (New England Biolabs).  PCR was performed with 30 cycles of {98°C 10 seconds, 
61°C 5 seconds, 72°C 1 minute} and a final cycle of {72°C 1 minute, 4°C hold}. 
The major gene specific 5’RACE PCR products were separated on a 0.8% agarose tris-
acetate EDTA gel with 1 kb and 100 bp DNA ladders (New England Biolabs).  Major products 
were excised, purified by spin cartridge and submitted for DNA sequencing with the T7 primer.  
The Universal Primer Mix primers contain a T7 priming site for direct PCR-product DNA 
sequencing.  
 
Figure 3.3 Genomic, Transcript and Tested Promoter Schematic 
(A) The GJA3 promoter is proposed to have a core promoter which contains the minimal sequences needed for 
constant transcription and a proximal promoter which contains the regulatory sequences of the gene.  (B) Predicted 
Cx46 mRNA sequence features based on NCBI database and genomic sequence analysis. P: Promoter; TSS: 
transcription start site; UTR: untranslated region; CDS: coding sequence; pA: polyadenine tail. 
 Results 
 In silico Analysis of the Genomic Structure of GJA3 
The human gene GJA3 has a simple but unique genomic structure (Figure 3.3).  
According to information obtained from the NCBI databases (Gene ID 2700; NC_000013.10, 
Build 37.3; NM_021954.3), the gene lies in reverse strand orientation, spanning 22,790 base 
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pairs (bp) located within the 13q12.11 region of genomic DNA.  13q12 also contains the genes 
GJB2 and GJB6.  The mature mRNA of GJA3 is predicted to be 5,219 bp in length comprised of 
two exons containing all of the necessary information to efficiently translate the coding 
sequence.  Exon 1 contains 155 bp of the 172 bp 5’ untranslated region (UTR), while exon 2 
contains the 17 bp directly upstream of the required translation-initiating ATG codon.  Exon 2 
also contains the entire coding sequence of Cx46 (1,308 bp = 435 residues), the 3’ UTR 
(predicted to be 3,703 bp in length), and the polyadenylation signal.  It is unclear if the sole 
17,571 bp intron plays an important role in gene regulation.  Very little is known about the 
functional regulation of the GJA3 gene under any disease associated physiological growth 
conditions but species specific differences have been found between hamsters (28). 
 
 
 
Figure 3.4. Schematic of the Human Cx46 Promoter 
1,177 base pairs upstream from the predicted transcription start site (TSS) were entered into promoter and 
transcription factor prediction web servers.  Predicted promoter sites with greater than 80% similarity to reference 
sequence were identified and marked with P.  The P* promoter was predicted as 100% probability with two different 
web server programs.  Transcription factors (grey boxes) were identified using the PROMO3.0 web program and the 
TRANSFAC 8.3 web database trained on human transcription binding sequence.  Restriction sites indicate the start 
of each tested promoter fragment used to elucidate the regulation of Cx46 gene expression.  Not to scale. 
 
The mRNA contains a premature in-frame stop codon 15 bp upstream of the initiator Met 
codon.  This may indicate early abortive translation to prevent unintended translation or to 
encode a novel internal ribosome entry site (IRES).  The data presented in Figure 3.2, show 
abundant use of Cx46 exon 1a, but it is the exon 1b that is used for lens expression.  This would 
be indicative of abortive transcription.  Abortive transcription would provide a means of tight 
control of expression and fit the idea of tight regulation in oxygenated tissues.  Interestingly, the 
3’ UTR is among the top 5% longest encoded in the human genome and spliced into mRNA 
(AceView: a comprehensive cDNA-supported gene and transcripts annotation, Genome Biology 
2006, 7 (Suppl 1):S12).   
Human transcription factor binding sites were predicted using a variety of web programs.  
Figures 3.1 and 3.4 both point out different TF predictions simply by using differently trained 
804      613    467            287                166    base pairs 
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programs.  Promo3.0 and TransFac2.0 (Figure 3.4) both use blast-like sequence in conjunction 
with a database trained on human TF binding sequences.  The early growth response (EGR 1-5) 
transcription factors are actively expressed under conditions of environmental stress and injury.  
Specific stresses include shear and mechanical stress (29), ultraviolet light, and by reactive 
oxygen species (ROS) (30).  ROS can be generated by UV catalysis, ischemia/reperfusion and by 
tissue hypoxia.  Myocyte enhancing factor 2 (MEF2; aMEF2 and RSRFC4 are related) is 
expressed in a variety of tissues including muscle, neural crest cells, endothelial cells, 
chondrocytes, neurons, and lymphocytes and contributes to tumorigenesis as well as epigenetic 
effects.  Some cellular functions that result from MEF2 activity include migration, signaling, 
neuromuscular junction building, ion transport, metabolism and contractility (31).  Nuclear factor 
erythroid-derived 2 45 kDa subunit (NF-E2 p45) is a transcription factor that is involved in 
mainly erythrocyte differentiation and maturation and is similar in function to the nuclear 
respiratory factor (Nrf) family of transcription factors that are upregulated and respond to 
cellular oxidative stress (32).  Oddly, Cx46 has not been found in these other cell types to date. 
The Aryl-hydrocarbon receptor (Ahr)/Aryl hydrocarbon nuclear translocator (ARNT) and 
hypoxia-inducible factors (HIFs 1-3) contribute to a number of biological responses under 
hypoxic and environmental stress growth conditions.  We are interested in the function of the 
HIFs in control of Cx46 expression because of the naturally hypoxic environment in which Cx46 
is preferentially expressed, the lens.  Ahr/ARNT activity is activated when genobiotics are 
present in the cell, allowing direct binding to Ahr/ARNT dimers and allowing efficient 
transcription of genes with DREs or XREs (dioxin or xenobiotic response elements) (33) in 
which Cx46 has three consensus sites in the core promoter region.   
 Luciferase-based Promoter Analysis under Hypoxia 
A luciferase-based approach was pursued as a means to understand regulatory regions 
located within the genetic code.  Various lengths of the promoter were amplified by PCR and 
ligated to the promoter-less luciferase reporter vector.  Each construct was tested in both N2A 
and HLE cells for activity.  Both the 1177 bp and 625 bp constructs of the human promoter do 
not respond to any mouse transcription factor signals in the N2A cell line as tested (Figure 3.5), 
however, N2A do not naturally express mouse Cx46.  Both promoter lengths exhibited low 
levels of transcription in N2A which may indicate differing control patterns of Cx46 expression 
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between human and mouse.  Many of the current mRNA transcripts analyzed in the literature 
regarding Cx46 come from mouse tissues.  When each construct was transfected into HLE cells, 
luciferase was efficiently produced in both normoxic and hypoxic growth conditions for 12 hours 
(Figure 3.5).  Although the level of transcription was not high there was a notable amount of 
luciferase activity detected.  We suspect Cx46 is transcribed at a near constant rate which is in 
ine with the dynamics of the gap junction life cycle.   
 
 
Figure 3.5 Non-normalized Cx46 Promoter Response to 21% and 1% Oxygen in Cell Culture 
N2A and HLEC cells were grown to 80% confluence then transfected with luciferase gene under the control of 
either CMV (control) or 625 bp (half) or FL (1177 bp) of the GJA3 promoter for 24 hours.  Cells were transferred to 
either 1% oxygen or kept in the normoxic incubator for 12 hours.  N2A cells (Left) do not transcribe Cx46 mRNA 
as well as HLEC cells (Right) in either oxygenated or hypoxic growth conditions.  Averages with standard variation 
shown. 
 
Next, luciferase production was measured in HLE cells under a 1% oxygen and 5% 
carbon dioxide atmosphere in fresh media.  Cells were near confluence when transfected to 
ensure connexin expression conditions.  Expression conditions may or may not be affected by 
cell-to-cell contact, mechanical shear stress (34), cell cycle, nutrient, and/or genotoxic stress 
(35).  When HLE cells were tested again under 1% oxygen growth conditions and luciferase 
activity was monitored, all tested promoter constructs responded to hypoxia when the data was 
normalized to the HIF reporter, as shown in Figure 3.6.  The 467 bp promoter fragment showed 
the largest increase in activity, characteristic of a promoter burst of activity.  The 287 bp 
fragment showed prolonged activity in 1% oxygen, so this promoter may be the minimal needed 
for sustained hypoxic expression. In other words, it may be the core promoter used for hypoxic 
expression of Cx46.  The longer promoter fragments showed more restriction over all time points 
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tested indicating the presence of negative regulators of expression.  It is possible that hypoxia-
induced transcription factors could bind upstream of the promoter and block transcription in a 
trans-inhibitor fashion.  Much of these assumptions need to be tested further to confirm this 
hypothesis. 
 
 
Figure 3.6.  The Cx46 Promoter Responds Quickly and Efficiently to 1% Oxygen 
HLE cells were transfected with each reporter vector and assayed at the given time for luciferase activity.  The 
shorter fragments respond quicker and are more robust than the longer fragments (>613 bp) indicating the control 
regions of the promoter. 
 
 5’-RACE Identifies Multiple GJA3 mRNA Species 
The advantage of using 5’-RACE for identifying the transcription start sites of genes is 
that the true transcription start point under any given growth condition can be identified.  The 
RACE analysis kit used allows for the “true” identification of the start site by use of a specific 5’ 
adaptor primer used for subsequent PCR amplification in conjunction with a reverse gene 
specific primer.  In this analysis, total RNA was purified from HLEC expressing endogenous 
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GJA3 under 21% and 1% oxygen for 24 hours.  This catches the hypoxia-adapted transcript of 
Cx46 in lens cells under the native growth conditions.  HLEC thrive during hypoxic growth but 
grow at a slower rate.  The goal was to use various Cx46 exon 1 specific reverse primers and the 
forward 5’RACE kit supplied primer to generate various RACE products of different sizes.  
These products have been analyzed by DNA sequence analysis to try to identify the 
transcriptional start sites in the GJA3 promoter under both normoxic and hypoxic growth 
conditions.  This method neither provides any evidence of IRES usage of which can be important 
in hypoxic regulation of gene translation nor does it test cell type specific effects. 
 
 
Figure 3.7.  5’RACE RNA Quality and PCR Control Reactions 
A) RNAs harvested from HLEC grown in 21% oxygen (N) or 1% oxygen (H) were separated by gel electrophoresis 
and analyzed for r18S and r28S RNA quality (1 µg and 2.5 µg total RNA per set).  B) Two different enzyme 
systems were used to generate the 5’RACE positive control (mouse transferrin receptor, 2.1 Kbp) and gene specific 
5’RACE internal positive control (mouse transferrin receptor nested primers, 0.38 Kbp) for the gene specific RACE 
amplification procedure.  Positive control is from mouse heart total RNA provided by the kit manufacturer.  Each 
lane contains 1, 2 or 3 µL cDNA for each control.  C)  RACE negative control performed with Phusion GC 
polymerase master mix and a single gene specific reverse primer; the gene specific primers are noted along with the 
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template cDNA used.  Very low non-specific products were detected above the predicted size range of each primer. 
Kbp: number of kilobase pairs; P#: gene specific primer number. 
  
The cDNA library construction step of the RACE experiment relies on the ability of the 
5’-adapted primer supplied in the kit to bind to all 5’UTRs present in the isolated mRNA.  The 
RACE experiment also depends on the correct PCR cycling parameters as well as usable gene 
specific reverse primers to ensure efficient binding and amplification of true RACE products.  
For these reasons, Figure 3.7 shows that the controls for the RACE procedure worked well with 
the gene specific primers and cycling conditions.  These conditions were used for the gene 
specific amplification step of the RACE experiment.  Figure 3.8 shows the results of the HLEC 
Cx46-specific amplification of 5’ cDNA ends from both 21% and 1% oxygen growth conditions 
over 24 hours. 
 
 
Figure 3.8.  Electrophoretic Analysis of 5’-RACE Products Produced by Using HLEC Total RNA and Cx46-
Specific Primers 
Two normoxic and five hypoxic 5’RACE products were isolated and sent for DNA sequencing with T7 sequencing 
primer.  Gene specific primers were generated using whole genome sequence data available at NCBI as a template.  
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Primers were individually BLAST searched to ensure GJA3-specific priming.  P#: Primer number; Kb: kilobase; bp: 
base pairs; black box: area cut for DNA extraction. 
 
Figure 3.8 also demonstrates the heterogeneity of 5’RACE products that were produced 
with Cx46-exon and 5’UTR specific primers.  Primer #5 primes to the end of the Cx46 coding 
sequence which lies in exon 2 and the expected product length is 1477 bp referenced to 
NM_021954.3 (NCBI GJA3 mRNA reference transcript).  Primers #36, #38 and #42 prime in the 
5’UTR and the expected product lengths are 88 bp, 21 bp, 110 bp, respectively.  Primers #65-
forward and #66-reverse prime the beginning and end of the Cx46 coding sequence, respectively.  
The forward primer is expected to not give any products, while the reverse primer is expected to 
give a 1480 bp product.  Actual product sizes vary due to a variety of reasons like primer 
sequence and PCR condition mispriming, unknown and alternative Cx46 mRNA isoforms, or an 
incomplete or misprimed initial reverse transcription reaction. 
 DNA Sequence Analysis 
DNA sequence analysis of the final purified PCR products gave mixed results.  The 
results of multiple PCR products that were co-purified gave traces that resemebled multiple 
products in the sequencing reaction.  This is indicative of 5’-RACE in which there is a wobbly 
transcription start site where transcription does not occur at a single site but rather a general area 
in the DNA sequence. 
 Discussion 
The promoter analysis used in this chapter indicates that Cx46 is expressed at low levels 
in the cellular environment and is upregulated for a short amount of time (<6 hours) by hypoxia.  
The core promoter is contained roughly within the immediate ~300 bp upstream of the predicted 
TSS.  Elevated transcription levels (>3-fold) were seen with the 287 and the 166 bp at all hours 
tested indicating an unregulated level of transcription when compared to the longer promoter 
fragments.  Further analysis is needed to confirm that the core promoter can be turned on in other 
epithelial cell lines. 
Of the many tissue types present in the human body, only the lens must express Cx46 to 
remain fully functional and disease free. Cx46 KO mice have only a noticeable cataract 
phenotype without any other notable differences compared to wild type littermates (36, 37).  
Cx46 expression has been identified in ROS 17/2.8 osteosarcoma cells, UMR 106-01 
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osteosarcoma cells, primary rat calvarial osteoblastic cells (24), and in neoplastic bone tissue 
(38), which are the only other tissues with Cx46.  This is an interesting observation because 
osteosarcomas originate in hypoxic bone tissue, an environment which is similar to the hypoxic 
environment found in the lens.  Koval et al. (1997) and Sanches et al. (2009) observed 
intracellular, perinuclear localization of Cx46 and gap junction plaques localized expression of 
Cx43, which we also observed in our lens cell culture system (27). Thus, a critical question is 
whether the Cx46 promoter is regulated by hypoxia.  
When the human promoter of Cx46 was challenged with 1% atmospheric oxygen in 
human lens cells and normalized to a HIF1α-responsive control promoter, we observed a 
transient ~17-fold increase in activity, indicating that hypoxia-responsive elements are most 
likely located within the proximal promoter region (Figure 3.6).  The Cx46 promoter also 
showed a sustained response with a shorter promoter fragment, suggesting that transcriptional 
regulation of Cx46 gene expression is tightly controlled by one or more positive and/or negative 
regulatory response elements present in the proximal promoter region.  Of course, the possibility 
of long-range transcriptional regulatory effects remains open.   
Analysis of the transcription start site by 5’-RACE gave mixed results.  There are 
multiple bands in most lanes of the 5’-RACE agarose gel and when individual bands were 
purified and sent out for direct sequencing, each single band gave data traces indicating varied 
transcription start sites.  Further analysis by cloning and clone isolation is warranted to sequence 
individual PCR products for the transcription start site or area. 
Hypoxia may play an active role in the Cx43/Cx46 regulation that occurs naturally in the 
lens or unnaturally in solid tumors and other ischemic tissues.  This possibility is being tested in 
lens cell cultures in addition to other tumor-derived cell lines and in other ischemic tissues. Tight 
regulation of Cx46 expression is not surprising since Cx46 is expressed primarily in the lens, but 
other lens crystallin proteins have been found in solid tumors as well, indicating that the 
conditions for lens protein expression exist in other tissues (39, 40).  The possibility that there is 
overlap in the available growth factors or other receptor ligands are open; however, given the 
uncommon expression of Cx46 in other tissues beyond the lens, the agonist and antagonist 
interactions that lead to Cx46 expression may have minimal overlap in both lens and solid tumor 
tissues.  One overlap may exist in prenatal developmental.  Here there are unique global and 
local hypoxic environments that are present and influence cellular differentiation (41-48), 
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however, Cx46 expression has not been studied throughout prenatal development.  This 
hypothesis still remains to be proven but offers interesting speculation into the unique role that 
Cx46 may play in physiology, independent of gap junction channel activity, which is associated 
with Cx46. 
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Chapter 4 - The Carboxy Terminal Tail Domain is Essential for 
Cx46 Function in Lens Cells 
Parts of this chapter were previously published as: 
Debarshi Banerjee*, Satyabrata Das*, Samuel A Molina, Dan Madgwick, Snehalata Jena, 
Leonie K Bossmann, Debjani Pal, Dolores J Takemoto.  “Investigation of the reciprocal 
relationship between the expression of two gap junction connexin proteins, connexin46 and 
connexin43” J Biol Chem. 2011 Jul 8; 286(27):24519-33. *Co-first Author 
 Abstract 
Connexins are the transmembrane proteins that form gap junctions between adjacent 
cells.  The function of the diverse connexin molecules is related to their tissue specific 
expression and highly dynamic turnover. Although multiple connexins have been previously 
reported to compensate for each other’s functions little is known about how connexins influence 
their own expression or intracellular regulation.  Of the three vertebrate lens connexins, two 
connexins, connexin43 (Cx43) and connexin46 (Cx46), show reciprocal expression and 
subsequent function in the lens and in lens cell culture.  In this study, we investigate the 
reciprocal relationship between the expression of Cx43 and Cx46. Forced depletion of Cx43, by 
tumor-promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), is associated with 
an upregulation of Cx46 at both the protein and message level in human lens epithelial cells. A 
siRNA-mediated downregulation of Cx43 results in an increase in the level of Cx46 protein 
suggesting that endogenous Cx43 is involved in the regulation of endogenous Cx46 turnover. 
Overexpression of Cx46, in turn, induces the depletion of Cx43 in rabbit lens epithelial cells. 
Cx46 induced Cx43 degradation is likely mediated by the ubiquitin-proteasome pathway as (i) 
treatment with proteasome inhibitors restores the Cx43 protein level and (ii) there is an increase 
in Cx43 ubiquitin conjugation in Cx46 overexpressing cells. We also present data which shows 
that the carboxy-terminal intracellular tail domain of Cx46 is essential to induce degradation of 
Cx43. Therefore, our study shows that Cx43 and Cx46 have novel functions in regulating each 
other’s expression and turnover in a reciprocal manner in addition to their conventional roles as 
gap junction proteins in lens cells. 
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 Introduction 
Gap junctions are intercellular aqueous channels composed of trans-membrane proteins 
called connexins (1). The gap junction-dependent or independent functions of connexins are 
important in the regulation of several cellular processes including growth, proliferation, 
differentiation, protection and cell death (2, 3). Distinct expression patterns and highly dynamic 
turnover rates are the key components that regulate tissue specific activity of different connexin 
molecules. The expression and turnover of connexins are fine-tuned balances of several 
processes such as gene expression, mRNA stability, protein synthesis and transport, and 
degradation (4,5). Connexin turnover and function is also modulated by several intrinsic and 
extrinsic factors including intra- and extracellular pH, various phosphorylation events, cellular 
status, and chemical reagents such as the tumor-promoting phorbol ester, 12-O-
tetradecanoylphorbol-13-acetate (TPA) (6-10). 
One tissue that relies on gap junction mediated communication for normal function and 
growth is the vertebrate lens. The lens is naturally avascular and, therefore, gap junction 
mediated functions play a major role in maintaining proper homeostasis and transparency of the 
lens. The vertebrate lens endogenously expresses three connexin proteins required for proper 
lens development and function, connexin43 (Cx43), connexin46 (Cx46), and connexin50 (Cx50) 
(11-17). These connexins show differential spatial distributions that are related to their specific 
functions at different regions of the lens. Cx43 and Cx50 are mainly expressed at the lens 
epithelium and are required to maintain gap junction activity at the surface of the lens (17, 18). 
However, Cx46 is preferentially expressed in the differentiating and mature fiber cells and 
therefore is the major functioning connexin in the lens nuclear region (15, 19). During lens 
epithelial-to-fiber cell differentiation Cx43 is substantially down-regulated and Cx46 is 
significantly up-regulated. This reciprocal expression between Cx43 and Cx46 is critical for 
maintaining connexin-mediated communication in lens tissue; however, the underlying 
molecular mechanism of this reciprocal relationship remains to be clarified. 
Previously, it was observed that Cx43 and Cx46 are reciprocally expressed in normal 
breast tissue and tumor xenografts (24), as well as in Y79 retinoblastoma xenografts (25). Cx43 
is well known for tumor suppressor functions and has been previously reported to be 
downregulated in breast tumor when compared to normal breast tissue (20-23). Two prior studies 
demonstrated that Cx46 is significantly upregulated in tumor xenografts and functions as a proto-
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oncogene favoring tumor growth while at an early hypoxic stage (24, 25). Therefore, the 
reciprocal expression between these two connexins plays a crucial role in the regulation of cell 
proliferation in tumorigenesis as well as in lens development. Multiple connexins expressed in 
the same tissue have been previously reported to compensate for each other’s function (4, 26, 
27), however, little is known about how one connexin can control the expression and turnover of 
another connexin.  
In the present study (previously published as Banerjee D, Das S, Molina SA, Madgwick 
D, Katz MR, Jena S, et al. Investigation of the reciprocal relationship between the expression of 
two gap junction connexin proteins, connexin46 and connexin43. J Biol Chem. 2011 Jul 8; 
286(27):24519-33; see original journal article for full details), we investigated the reciprocal 
relationship between the expression of these two connexin proteins, Cx43 and Cx46. We showed 
that TPA forced depletion of Cx43 protein and this is associated with an upregulation of Cx46. 
The upregulation of Cx46 is both at the mRNA and protein level and occurs via a protein kinase 
C (PKC) dependent pathway in human lens epithelial cells (HLEC). Additionally, siRNA 
mediated downregulation of Cx43 resulted in an increase of Cx46 indicating that endogenous 
Cx43 is involved in the control of Cx46 protein levels. Further and in this chapter, we showed 
that overexpression of Cx46 causes a reduction of Cx43 protein. Overexpression of Cx46 
increased Cx43 ubiquitination and therefore mediated its degradation by a proteasome dependent 
pathway. In this chapter, I provide evidence that Cx46 membrane localization is not necessary 
for induction of degradation and that only the cytoplasmic carboxy-terminal tail domain of Cx46 
is required to induce degradation of Cx43, although these two proteins failed to co-localize. Our 
results provide mechanistic insight into the regulation of Cx43 and Cx46 in lens cells and offers 
explanation of the reciprocal relationship observed unnaturally in tumor xenografts and naturally 
in the vertebrate lens. 
 Materials and Methods 
 Cell Culture 
To assure the results of this publication both human and rabbit lens epithelial cells were 
used. Immortalized human lens epithelial cells (HLEC) and rabbit lens epithelial N/N1003A 
cells (NN or N/N) were cultured as described previously (24).  Briefly, cells were cultured in low 
glucose DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% premium fetal bovine serum 
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(Atlanta Biologicals, Atlanta, GA) to at least 70% confluence prior to using for experimentation.  
Cells were grown in a humidified atmosphere of 5% CO2 and 37°C. All cell culture plastics were 
purchased from Midwest Scientific (St. Louis, MO). 
 Cloning and Transfection 
The coding region of rat Cx43 (NM_012567.2, 382 residues), rat Cx46 (NM_024376.1, 
416 residues), or rat Cx50 (NM_153465.2, 440 residues) was sub-cloned into the pEGFP-N3 
vector (Clontech, Mountain View, CA) to create carboxy-terminal tagged EGFP fusion proteins. 
Plasmid transfection was mediated by Lipofectamine 2000 (Invitrogen) at 70-80% confluency 
according to the manufacturer’s suggestions. The transfected cells were grown in the presence of 
1 mg/mL G418 for 3-4 weeks for the selection of positive colonies. Then, the positive colonies 
were isolated and grown in media containing 500 µg/mL of G418, thereafter.  
      Wild type rat Cx46 was subcloned into pEGFP-N3 (Clontech) using the forward 
primer: ratGJA3 N3 F PCR 5’-GCAGAATTCAGGATGGGCGACTGGAGC-3’ and the reverse 
primer: rCx46 R 5’-TATGGATCCGATGGCCAAGTCACCTGGTCTG-3’.  Various mutants 
were created to test the effect of the Cx46 carboxy-terminal domain on Cx43.  The Cx46Δ413 
mutant is truncated before the ZO-1 interaction site (DLAI ) in the carboxy-terminal tail domain.  
The Cx46Δ398 mutant has the majority of the PCK phosphorylation sites truncated from the 
wild type protein.  Cx46Δ325 contains the WT protein truncated half way through the CT 
domain, ending at residue 325.  The Cx46Δ225 mutant encodes the NT domain and the four 
transmembrane domains of the wild type protein and just deletes the Cx46 carboxy-terminal 
(CT) tail domain (also labeled as Cx46-dCT).  Each mutant was cloned by PCR using the 
forward primer ratGLA3 N3 F PCR (above) and the following matched reverse primers: 
Cx46Δ413: rCx46d413-416 5’-TATGGATCCACCTGGTCTGGCTCGTCCGCT-3’; Cx46Δ398: 
rCx46d398-416 5’-TATGGATCCGTCCAGGAGGACCAACGGTGG-3’; Cx46Δ325: 
rCx46d325-416: 5’-TATGGATCCGTGGTGGCCATTGCAGTGCTTGAC-3’; Cx46Δ225: 
rCx46d225-416R 5’-TATGGATCCCATGTTGAGCACCAGTGACGCACA-3’.  Amino acid 
residues 225-416 of wild type Cx46 were sub-cloned into pEGFP-N3 to generate an expression 
vector which expresses only the CT tail domain of Cx46 fused to EGFP using 46tail225-416F 
5’-ATAGAATTCATGCTAGAGATTTACCACCTGG-3’ as the forward primer and rCx46 R as 
the reverse primer.  Wild type rat Cx46 cDNA was also sub-cloned into the pQE-TriSystem 
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vector (Qiagen, Valencia, CA) to generate a C-terminal 5x-His tagged protein (courtesy of Dr. 
Debarshi Banerjee). The expression of Cx43-EGFP, Cx46-EGFP, Cx50-EGFP, Cx46Δ225-
EGFP (Cx46-dCT-EGFP), Cx46Δ325-EGFP, Cx46Δ398-EGFP, Cx46Δ413-EGFP, Cx46Δ1-
225-EGFP (Cx46Tail-EGFP), and Cx46-His were checked by western blot analyses using anti-
GFP and anti-His tag antibodies, respectively. 
 Whole Cell Homogenate (WCH) Preparations 
Cells were washed 3 times with cold phosphate-buffered saline (PBS, pH 7.2), collected 
by scraping from plates, and centrifuged at 4000 rpm for 5 min at 4°C. The cell pellets were 
lysed in ice cold 1X RIPA buffer [10 mM Tris-HCl (pH 7.5),150 mM NaCl, 1 mM Na2EDTA, 1 
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin] containing 1 mM PMSF. Cell lysates 
were sonicated for 10 seconds (3 times) and protein concentration of each sample was measured 
using Bio-Rad Protein Assay.  
 Western Blotting and Antisera 
Western blot analyses were performed as previously described (24, 25, 28). Mouse anti-
N-terminal-Cx43 (anti-Cx43 NT) was purchased from Fred Hutchinson Cancer Center (Seattle, 
WA); rabbit anti-phospho-Cx43 (Ser-368) from Cell Signaling Technologies (Danvers, MA); 
rabbit anti-C-terminal-Cx43 (anti-Cx43 CT, 1:5000) and mouse anti-β-actin (1:10000) from 
Sigma-Aldrich (St. Louis, MO); rabbit anti-Cx46 (1:2000) from US Biologicals (Swampscott, 
MA); mouse anti-Cx50 (1:4000) from Zymed-Invitrogen (San Francisco, CA) and mouse anti-
EGFP antibody (1:5000) was purchased from Clontech (Mountain View, CA). Mouse anti-
pentahis tag (1:1000) was purchased from Qiagen (Valencia, CA). Mouse anti-ubiquitin antibody 
was purchased from Calbiochem (EMD Biosciences, OH). Rabbit anti-C-terminal-Cx43 (anti-
Cx43 CT) was used to detect Cx43, if not mentioned otherwise. 
 Immunofluorescent Labeling and Fluorescent Microscopy 
HLECs and NN1003A cells were grown on glass coverslips in six-well plates until 80% 
confluency. Treatments were carried out per experimental protocol. Cells were fixed with 4% 
formaldehyde in PBS for 20 min at room temperature, quenched with 50 mM glycine, washed 
with PBS, permeabilized with 0.05% Triton-X100 in PBS for 30 min, washed, and blocked with 
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5% BSA (blocking solution) in PBS for at least 1 h at room temperature. Cells were then treated 
overnight at 4°C with rabbit anti-Cx43CT antibody (1:250) or rabbit anti-Cx46 antibody (1:250) 
in blocking solution with constant gentle rocking. After washing three times for 5 min each in 
PBS, slides were labeled for 10 min in the dark at room temperature with 500 nM DAPI in PBS 
to stain nuclei. Finally, after three more washes for 5 min each in PBS, slides were mounted in 
Prolong Gold Antifade Reagent (Invitrogen-Molecular Probes, Eugene, OR) for at least 24 hours 
prior to visualization. The slides were viewed by a confocal microscope (LSM 510 Meta, Carl 
Zeiss, Göttingen, Germany) or by a fluorescence microscope (Axiovert 200M, Carl Zeiss). For 
fluorescence studies involving transiently transfected cells, NN1003A or HLEC cells were 
transfected with plasmids encoding Cx46-EGFP and mutants for no more than 48 hr prior to 
formaldehyde fixation.  Monoclonal anti-58K/FTCD antibody (1:50, Sigma-Aldrich) was used in 
conjunction with donkey anti-mouse-Alexa Fluor 594 antibody (1:800, Invitrogen) to mark the 
Golgi apparatus in HLECs. 
 siRNA Transfection 
HLEC were grown in 60 mm dishes. When confluency reached 70%, cells were treated 
with 50 nM of either anti-Cx43 siRNA (Qiagen) or All Stars Negative Control siRNA (Qiagen) 
and 20 µL of HiPerFect transfection reagent (Qiagen). Cells were harvested after 24 and 48 
hours of transfection and WCH were prepared.  
 Statistical Analyses 
Origin software (Microcal Software Inc., Northampton, MA) was used to generate 
statistical analyses and associated data graphs. The level of significance (see * in figure legends) 
was considered at p < 0.05 using paired t test analyses. All data are presented as mean ± SEM of 
at least 3 independent experiments. 
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 Results 
For full results of published paper, please see the original journal article.  This chapter 
contains data generated by myself and sometimes in conjunction with fellow lab mates, as noted. 
 siRNA Mediated Knockdown of Endogenous Cx43 Results in  
Increased Cx46 Protein Levels in HLEC 
As part of this study, Dr. Satyabrata Das found that pretreatment with a PKC inhibitor 
blocked the TPA-induced Cx43 degradation that occurred concomitantly with the inhibition of 
TPA-induced increase in Cx46 protein. This led us and Dr. Debarshi Banerjee to speculate 
whether the degradation of Cx43 is necessary for the increase of Cx46 protein. To check this, we 
silenced Cx43 expression by a selective anti-Cx43 siRNA and examined the effect of Cx43 
downregulation on Cx46 protein levels. As shown in Figure 4.1, transfection of HLECs with 
anti-Cx43 siRNA decreased the Cx43 protein levels significantly after 48 hours. Interestingly, 
the decrease in Cx43 protein level (Figure 4.1B) was associated with a notable increase in Cx46 
protein at 48 hours of siRNA transfection (Figure 4.1C). However, treatment with anti-Cx43 
siRNA did not cause a change in the amount of Cx50 protein (Figure 4.1A). This data indicates 
that endogenous Cx43 is involved in the regulation of Cx46 protein expression in HLECs and 
further confirmed the endogenous reciprocal relationship of Cx46 and Cx43 expression. 
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Figure 4.1 siRNA-Mediated Knockdown of Cx43 Results in Increased Cx46 
Protein Levels 
(A) 70% confluent HLECs were treated with 50 nM of either anti-Cx43 siRNA or 50 
nM of AllStars Negative Control siRNA for the indicated time periods. Increase in 
Cx46 level was noticed at 48 h of anti-Cx43 siRNA treatment when Cx43 was 
maximally down-regulated. (B) and (C) densitometric analyses show siRNA-
mediated selective down-regulation of Cx43 causes an increase in Cx46 protein 
levels. Data are represented as mean ± S.E. *, significant statistical difference (p ≤ 
0.05) between indicated data and control (at 0 h); **, statistical insignificance 
between the data and control (at 0 h). 
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 Overexpression of Cx46 Causes a Decrease in Cx43 Protein  
Levels in N/N1003A Rabbit Lens Cells 
Since the degradation of Cx43 was associated with an up-regulation of Cx46, we next 
investigated if overexpression of Cx46 had an effect on Cx43. To examine this, we stably 
overexpressed the Cx46-EGFP fusion protein in rabbit lens epithelial N/N1003A cells and 
analyzed the effect of Cx46 overexpression on the other lens connexins endogenously present in 
these cells as well as other membrane proteins. The Cx46-EGFP expressing cells showed the 
expression of fusion protein as two distinct bands around 75 kDa as determined by western blot 
using an anti-EGFP antibody (Figure 4.2A). The two bands in Figure 4.2A are suspected to be 
phospho-Cx46-EGFP isoforms. Interestingly, stable overexpression of Cx46 decreased the Cx43 
protein levels of the phosphorylated isoforms P0, P1 and P2. Stable overexpression of Cx46 
reduced the Cx43 protein levels to 50% when compared to untransfected or EGFP transfected 
cells (Figure 4.2B). However, Cx50 protein level was not changed due to the stable 
overexpression of Cx46 (Figure 4.2A and 4.2C). We also examined the effect of overexpression 
of Cx50 on Cx43 protein levels. Stable overexpression of Cx50-EGFP had no effect on Cx43 
protein levels (Figure 4.2D). Collectively, these data indicate that only Cx46 influences the 
decrease of Cx43 and that another closely related alpha-type connexin, Cx50, does not. 
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Figure 4.2 Overexpression of Cx46 Causes a Reduction in Cx43 Protein Levels in Rabbit Lens Epithelial 
N/N1003A Cells 
(A) Western blot analyses of Cx46-EGFP, Cx43, Cx50, tubulin, and Na
+
/K
+
ATPase in untransfected control cells 
and in cells stably overexpressing EGFP or Cx46-EGFP. Whole cell lysates were made, and equal amounts of total 
protein were run in SDS-PAGE followed by immunoblot. The blot was probed with anti-EGFP antibody to detect 
Cx46-EGFP expression. The blots were also probed with Cx43CT (against C-terminus) and Cx43NT (against N 
terminus) antibodies to detect Cx43 to rule out any C-terminal truncation of Cx43. (B) Densitometric analyses 
showed significant reduction of Cx43 protein levels in Cx46-EGFP stably transfected N/N1003A cells, whereas (C) 
The level of Cx50 protein showed no change. The bands representing Cx43, Cx50, and tubulin were digitized by 
UN-SCAN-It gel software. The average pixel values were calculated for Cx43 bands, normalized against average 
pixel values for loading control (tubulin), and then plotted in percent of control. Data are represented as mean ± S.E. 
of three independent experiments. *, Significant statistical differences (p ≤ 0.05) between indicated data and control 
cells. (D) Overexpression of Cx50 does not cause a decrease in Cx43 protein levels. N/N1003A cells were stably 
transfected with plasmid encoding Cx50-EGFP. Cell lysates were prepared, and equal amounts of total protein were 
run on SDS-PAGE followed by Western blot. The Cx50-EGFP and Cx43 proteins were detected by probing the 
blots with EGFP and Cx43 antibodies, respectively. 
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 Cx46 is Predominantly Localized to the Intracellular Compartments in  
N/N1003A and HLEC Lens Cells 
We determined the intracellular localization of Cx46 in the stably transfected cells by 
intrinsic EGFP fluorescence (Figures 4.3 and 4.4) and immunofluorescence microscopy (Figures 
4.5 and 4.6).  Green fluorescence of Cx46-EGFP expression was predominantly detected to an 
intracellular perinuclear compartment (Figure 4.3, 4.4, and 4.6A).  Fluorescence signal of Cx46-
EGFP was not observed at the plasma membrane region.  In Figure 4.3, it can be noted that wild 
type Cx46 does not traffic well to the plasma membrane of mouse N2A cells when the cells are 
either opposed or free and that acute 1% oxygen does not affect this trait.  However, the carboxy-
terminal tail deletion mutant shows diffuse localization different than that of EGFP and wild type 
Cx46.  This is most likely due to the loss of sorting and/or packaging transport ability because of 
the truncation.  The CT domain of any connexin contains many cryptic signals that are yet to be 
understood.  However, hypoxia seems to not affect localization of the wild type Cx46 protein.  
Overall Cx46-EGFP proteins fluorescence increased when subjected to hypoxia but the 
differences were not quantitated for this study.  Figure 4.4 highlights the trafficking and 
truncation correlation further by displaying each of the mutant subcellular localizations.  All 
mutants except the Cx46Δ1-225 (Cx46-Tail) and Cx46Δ225 (Cx46-dCT) domains localized in 
punctate perinuclear structures.  The two exceptions displayed diffuse expression patterns 
suggesting that all domains are necessary for correct protein trafficking with the signals for 
oligomerization/stabilization being contained in amino acid residues 226-325.  However, for 
complete and correct construction of connexons, residues 226-325 must be connected to the first 
225 residues of Cx46.  Cx46 localization does not seem to be largely affected by the PKC 
activator TPA (Figure 4.5B) whereas Cx43 is negatively affected (Figure 4.5A) by TPA 
treatment (Dr. Satyabrata Das).  Again, wild type Cx46 is punctate and perinuclear (Figure 
4.5C). 
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Figure 4.3 Intracellular Localization of Rat Cx46-EGFP in Mouse N2A Cells 
Mouse N2A cells were transiently transfected with either EGFP, wild type Cx46 (Cx46WT-GFP), or a Cx46 
deletion mutant where the entire carboxy-terminal tail domain is truncated at residue 225 (Cx46dCT-GFP).  Wild 
type Cx46 (middle) shows perinuclear (nuclei: blue) localization under both normoxic and acute 1% oxygen 
conditions, whereas the truncated Cx46 mutant (right) is perinuclear and diffuse, similar to EGFP only (left).  The 
difference in localization and packaging can be attributed to the loss of cryptic molecular signals contained in the 
CT domain of all connexins. 
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Figure 4.4 Intracellular Localization of Rat Cx46 Protein Mutants Labeled with 
EGFP in Human Lens Epithelial Cells 
Punctate Cx46-EGFP proteins were localized to the perinuclear region for all 
mutants except for the Cx46Δ225 (Cx46-dCT) CT domain deletion and the Cx46Δ1-
225 NT (Cx46-Tail), and transmembrane domain deletion mutants.   
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Figure 4.5 TPA-Induced Changes in Localization of Cx43 and Cx46 in HLECs 
(A, credit to Dr. Satyabrata Das) HLECs were treated with or without 300 nM TPA for different time periods as 
indicated in the figure and labeled with anti-Cx43 antibody (green). DAPI (blue) was used to stain nuclei. Arrows 
point to the gap junction plaques at the membrane or in the cytosol. (B, credit to Dr. Debarshi Banerjee) Control 
HLECs or TPA-treated (300 nM, 6 h) HLECs were labeled with anti-Cx46 antibody (green) and DAPI (blue). Cx46 
staining was found predominantly in the intercellular compartments of HLEC cells. (C) Fluorescence microscopy of 
HLEC cells transiently expressing either EGFP (green) or Cx46-EGFP (green) with DAPI staining of the nuclei 
(blue). Again, Cx46-EGFP localized to the perinuclear region. 
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The EGFP protein is a rather large fusion protein tag and has a molecular weight of 27 
kDa. Therefore, we speculated whether EGFP tagging at the C-terminus of Cx46 prevented it 
from reaching the cell surface. To investigate this, we transfected cells with a plasmid encoding 
Cx46-His, which encodes six histidine residues fused to the carboxy-terminus of Cx46. We then 
examined the localization of Cx46-His fusion protein via immunofluorescence in order to assess 
differences in the localization of Cx46. Immunofluorescence using the anti-His antibody also 
demonstrated that Cx46 localized predominantly to the intracellular perinuclear compartments 
and not to the plasma membrane (Figure 4.6B, red channel). 
     To confirm the localization of Cx46, untransfected or stably transfected cells were 
fractionated to isolate plasma membrane proteins. Western blot analyses with antibodies against 
EGFP and Cx46 detected no immunoreactive bands that corresponded to endogenous or Cx46-
EGFP or Cx46 protein in the plasma membrane fraction of untransfected or transfected cells 
(Figure 4.6C). In all the preparations of plasma membrane fractions, a marker for plasma 
membrane (Na
+
/K
+
ATPase) was enriched; meanwhile, the cytosolic marker GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) was not, confirming the purity of the membrane 
fractions. 
     To further demonstrate that EGFP-tagging does not affect the localization of connexin 
proteins in N/N1003A cells, cells were transiently transfected to express Cx43-EGFP. Using 
western blot analysis, Cx43-EGFP fusion protein (around 70 kDa) was detected in plasma 
membrane fractions isolated from Cx43-GFP overexpressing N/N1003A cells (Figure 4.6D). 
These data clearly suggested that EGFP tagging had no influence on the Cx43 or Cx46 transport 
and localization within the lens cell. Our data are consistent with other literature confirming that 
C-terminal tagging of connexins does not inhibit their intracellular transport (41, 42). 
     Since Cx46 is localized to the perinuclear region, we further characterized which 
compartment Cx46 is localizing to by using three-color fluorescence microscopy.  Figure 4.6E 
shows that Cx46-EGFP localizes to the perinuclear region in HLECs but does not co-localize 
well with the Golgi marker 58K/FTCD protein.  This suggests that Cx46-EGFP could reside in 
the endoplasmic reticulum compartment of HLECs. 
108 
 
Figure 4.6 Cx46 Protein is Predominantly Localized to the Intercellular Compartments in Lens N/N1003A 
Cells 
(A) Fluorescence microscopy images of NN1003A cells stably overexpressing Cx46-EGFP. All cells were fixed and 
stained with DAPI to visualize nuclei. (B) The localization of Cx46-His protein (penta-histidine-tagged) in 
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N/N1003A cells. Cells were transfected with plasmid encoding Cx46-His and, after 24 hr of transfection, cells were 
fixed, permeabilized, and labeled with penta-histidine antibody (red) and DAPI (blue). (C) Western blot analyses 
were performed for Cx46 (with anti-EGFP or anti-Cx46) on equal amounts of total protein from lysates of Cx46-
EGFP-expressing cells (lane 1) and plasma membrane protein fractions isolated from untransfected control cells 
(lane 2) or Cx46-EGFP stable (lane 3) cells. The blots were also probed with antibodies against a plasma membrane 
marker Na
+
/K
+
ATPase, and a cytosolic marker (GAPDH) to demonstrate the purity of plasma membrane protein 
extracts. (D) Western blot analyses show the localization of Cx43-EGFP in the plasma membrane of Cx43-EGFP-
expressing N/N1003A cells. Cells were transiently transfected with plasmid encoding Cx43-EGFP for 24 hr. Then, 
the cells were fractionated into plasma membrane protein fractions. Equal amounts of total protein of lysate and 
plasma membrane fractions of Cx43-EGFP expressing cells were subjected to Western blot analyses with antibodies 
against EGFP, Na
+
/K
+
ATPase, GAPDH, and calnexin (an ER marker). (E) Fluorescence microscopy images of 
HLEC cells expressing Cx46-EGFP (green) that were fixed, permeabilized, and labeled with 58K/FTCD antibody 
(red, a Golgi marker) and DAPI (blue). Cx46-EGFP did not co-localize well with the Golgi marker. NN: N/N1003A 
cells.  Data in panels A-D were collected with Dr. Debarshi Banerjee. 
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Figure 4.7 Protein Sequence Alignment of Rat Cx43, Cx46, and Cx50 and Schematic of Cx46 Mutants 
(A) The amino acid residues of Cx43, Cx46, and Cx50 are given as a ClustalW alignment produced with Lasergene 
9 MegAlign software (DNAStar, Inc., Madison, WI). Sequences are numbered according to the Cx46 sequence. The 
NCBI reference sequences used are NP_036699.1 for Cx43, NP_077352.1 for Cx46, and NP_703195.2 for Cx50. 
(B) Schematic diagram of wild-type Cx46 and Cx46 C-terminal deletion mutant (Cx46dCT, deletion of amino acids 
225–416), as well as a schematic of the Cx46 tail domain mutant (Cx46Tail, deletion of amino acids 1–224). 
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 The Carboxy-Terminal Tail Domain of Cx46 is Necessary  
and Sufficient for Induction of Cx43 Degradation 
Primary amino acid sequence alignments of rat Cx43, Cx46, and Cx50 show significant 
sequence similarity at their N-terminal and transmembrane domains similar to that of all alpha-
type connexins (48).  The major variability in the amino acid sequences of Cx43, Cx46, and 
Cx50 are found at the cytoplasmic carboxy-terminal tail domain (Figure 4.7A). Since Cx50 
overexpression was not found to mediate Cx43 degradation, we speculated whether the C-
terminal tail domain (amino acids 225-416) is the active domain of Cx46 that induces Cx43 
degradation. To test this hypothesis, we created two Cx46 mutants.  One mutant contains the N-
terminus and all four transmembrane domains (amino acids 1-225, named Cx46dCT).  The other 
Cx46 mutant contains amino acids 225-416, which encode only the C-terminal tail domain 
(named Cx46Tail). Each mutant is expressed as an EGFP fusion protein, similar to Cx46-EGFP 
(Figure 4.7B). 
Next, we transfected N/N1003A cells with either the plasmid encoding wild type Cx46-
EGFP, Cx46dCT-EGFP, or Cx46Tail-EGFP, and then analyzed the effect of mutant Cx46 
protein on the Cx43, Cx50, Na
+
/K
+
ATPase, and ZO-1 protein levels (Figure 4.8A-D). Cx46dCT-
EGFP was expressed at the predicted molecular weight of ∼50 kDa as determined by western 
blot using anti-EGFP antibody (Figure 4.8A). Notably, overexpression of Cx46dCT-EGFP did 
not induce Cx43 degradation at 24-48 hr after transfection (Figure 4.8A). The role of the C-
terminal tail domain of Cx46 in inducing Cx43 degradation was confirmed by overexpressing 
Cx46Tail-EGFP. Overexpression of Cx46Tail-EGFP (Figure 4.8C), like wild type Cx46-EGFP 
(Figure 4.8B), was able to cause a reduction of Cx43 protein at 24 hr and 36 hr of transient 
transfection (Figure 4.8D). Additionally, Cx46Tail-EGFP exhibited no specific localization 
within HLECs as shown by fluorescence microscopy (Figure 4.8E). These data demonstrate that 
the carboxy-terminal cytoplasmic tail domain of Cx46 is responsible for inducing the 
degradation of Cx43 in lens cells.  Similarly, Figure 4.9 shows that the degradation feature of 
Cx46 depends on its carboxy-terminal tail and that the effect is unique to only the Cx46 effect on 
Cx43 stability.  Cx50 does not have this same effect.  Figure 4.10 shows that each mutant 
expressed the desired product in the cells tested in this study. 
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Figure 4.8 The C-Terminal Tail Domain of Cx46 is Required for Cx43 Degradation 
(A) Over-expression of a Cx46 deletion mutant (Cx46dCT-EGFP) does not induce Cx43 degradation. Western blot 
analyses of Cx46dCT-EGFP and Cx43 in untransfected cells (0 hr) or in cells transiently transfected with plasmid 
encoding the Cx46 deletion mutant (Cx46dCT-EGFP). The expression of Cx46dCT-EGFP was confirmed by 
probing the blot with the EGFP antibody. The blot was also probed with Cx43CT and β-actin antibodies. (B) 
NN1003A cells were transiently transfected with full-length Cx46-EGFP, and whole cell lysates were prepared after 
12, 24, and 36 hr post-transfection. Equal amounts of total protein were analyzed by 10% SDS-PAGE followed by 
immunoblot. The blots were probed with antibodies to detect EGFP, Cx43, Cx50, Na
+
/K
+ATPase, and β-actin. 
There is no change in any of the protein levels of membrane-associated proteins Cx50 or Na
+
/K
+
ATPase, indicating 
that overexpression of Cx46-EGFP only affects Cx43 protein levels. (C) Over-expression of the Cx46 C-terminal 
tail domain (Cx46Tail-EGFP, residues 225–416 of wild type) in NN1003A cells caused reduction in Cx43 protein 
levels after 24 and 36 hr of transient transfection. This provides evidence that the CT tail domain of Cx46 induces 
the degradation of Cx43 through either direct or indirect interaction.  (D) Densitometric analysis of Western blots 
used in B and C. Blots were digitized by UN-SCAN-It gel software. The average pixel value was calculated for all 
protein bands, normalized, and plotted in percent of control (β-actin). Data are represented as the mean of two 
independent experiments with S.E.M. shown. (E) Fluorescence microscopy of HLECs expressing Cx46Tail-EGFP. 
The tail domain did not localize to any specific intracellular compartment, confirming cytoplasmic expression and 
not membrane association. 
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Figure 4.9 Effect of Cx46, Cx50 and the Cx46-Tail Deletion Mutant on Cx43 Protein Levels in N/N1003A 
Cells 
(A) Immunoblot showing the Cx46 specific effect on reducing Cx43 protein levels with two different primary 
antibodies against Cx43.  (B)  Cx50 expression does not affect Cx43 protein expression over 48 hours.  (C)  Cx46 
expression results in a reduction in the Cx43 protein levels while there was no change in Cx50 protein expression 
during the same experiment.  (D)  When the CT domain of Cx46 is deleted (Cx46d225-416), the reduction in Cx43 
protein levels is abolished.  This indicates that the minimum necessary domain for Cx43 interaction is the CT tail 
domain, which is predicted to be unstructured (an intrinsically disordered region). 
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Figure 4.10 Western Blot of the Expression Pattern of Various Cx46 Tail Deletion Mutants 
Cx46 mutants were expressed in mouse N2A and rabbit N/N1003A cells and western blotted for EGFP.  This 
ensures each mutant is expressed although at various levels within each cell type. 
 
 Discussion 
In the present study we investigated the reciprocal relationship between expression and 
turnover of two gap junction connexin proteins, Cx43 and Cx46, in lens epithelial cells. The use 
of vertebrate lens as a system to study gap junction communication and connexins function has 
been increasing in recent years. The developing lens also serves as a highly accessible paradigm 
for the universal study of cell proliferation, epithelial function, and cell differentiation, as well as 
studies of hypoxia. Here we show that TPA induces internalization and degradation of Cx43 in 
human lens epithelial cells. Previously, we have reported the association of PKCγ with Cx43 in 
response to TPA-treatment in HLECs (28, 37). TPA induced Cx43 hyper-phosphorylation and 
internalization from membranes has been well established in the cultured rat liver epithelial cell 
line IAR20 (31). In HLEC, TPA induced degradation of Cx43 was associated with an increase in 
phosphorylation of S368 of Cx43 and treatment with PKCγ inhibitor prevented the 
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phosphorylation at this residue and Cx43 degradation. Therefore our study shows that the PKCγ 
mediated phosphorylation of Cx43 on S368 acts as a critical signal for internalization and 
degradation (credit to Dr. Satyabrata Das for PKCγ work).  
The reciprocal expression of Cx43 and Cx46 was further observed in rabbit lens 
epithelial cells overexpressing Cx46-EGFP.  These cells exhibited a reduction of endogenous 
Cx43 protein levels. We confirmed the reduction of all three phospho-isoforms of Cx43 protein 
(P0, P1, and P2) by western blotting with antibodies against C-terminal and N-terminal domains.  
This precaution aids in ruling out the possibility that proteolytic cleavage of Cx43 epitopes may 
be contributing to the reduction of Cx43 observed via western blotting. 
Several studies have previously reported the involvement of both proteasomal and 
lysosomal pathways in the degradation of connexins (4, 43-45). The lysosomal pathway was 
shown not to be involved in the degradation of Cx43 when it is internalized from cell 
membranes. Treatment with lysosome inhibitors leupeptin and chloroquine showed no effect on 
the degradation of Cx43 in Cx46-EGFP expressing cells. But, the treatment with proteasome 
inhibitors ALLN and MG132 strongly counteracted Cx46-induced Cx43 degradation. In 
addition, co-immunoprecipitation analyses showed an increase in Cx43 ubiquitination associated 
only with Cx46-EGFP expressing cells. Together, these results suggest that Cx46-induced 
degradation of Cx43 is mediated by the ubiquitin-proteasome pathway while the lysosome 
degradation pathway does not appear to be involved (credit to Dr. Debarshi Banerjee for 
degradation pathway work). 
In this study, we observed that Cx46 is mainly localized to the intracellular compartments 
of lens epithelial cells. Even upon overexpression of Cx46 or after TPA treatment, the 
localization of Cx46 was not detected in the plasma membrane, as determined by confocal 
immunofluorescence and EGFP-intrinsic fluorescence microscopy.  This was further confirmed 
by western blot analyses of cellular fractions. The intracellular localization of Cx46 was also 
shown in bone osteoblast (39) and lung alveolar cells (40). Conventional techniques such as 
fluorescence microscopy and western blots do not completely rule out the possibility of 
membrane localization of Cx46 in our lens cultures because Cx46 has a major membrane-
localized function in vivo in the lens. Connexins have rapid turnover rates with half-lives of a 
few hours (50-52). Therefore, if Cx46 is rapidly internalized after being delivered to the plasma 
membrane, it would not be detectable at the cell surface by conventional techniques. 
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Nonetheless, since membrane localization was not observed, it is unlikely that overexpression of 
Cx46 induced Cx43 degradation by facilitating loss from the plasma membrane. 
Due to its observed intracellular localization, Cx46 is likely to induce Cx43 degradation 
by a gap junction independent mechanism. This leads us to speculate two possibilities for the 
degradation of Cx43.  One, that endoplasmic reticulum associated degradation (ERAD) mediates 
the Cx46-induced degradation of ubiquitinated Cx43 species observed in our studies (either 
folded or unfolded Cx43).  Or two, Cx46 associates with Cx43 either directly or indirectly in the 
ER prior to transit to the cellular membrane and induces the degradation of Cx43 outside of the 
ER.  Nonetheless, these hypotheses need to be thoroughly tested. 
Additionally, the Cx46dCT-EGFP mutant failed to induce Cx43 degradation. However 
overexpression of the Cx46Tail-EGFP mutant, which localizes to the cytoplasm, caused a 
reduction of Cx43 protein levels. This is interesting because the Cx46Tail mutant does not 
contain the membrane anchoring signals found in the amino-terminus of Cx46, yet it can still 
trigger degradation of endogenous Cx43. It is possible that Cx46Tail stimulates ERAD of Cx43 
during translation but this does not rule out potential Cx46Tail interactions with Cx43 at the 
plasma membrane. Therefore, it is likely that Cx46 mediates its action through putative binding 
partners at the C-terminal tail domain.  The cytoplasmic tail domain of Cx46 has predicted 
binding sites for various kinases, such as PKCγ, CK-1, Akt/PKB, and MAPK, among others.  It 
is also predicted to be rather unstructured, so it could take on altered functional conformations 
depending upon its binding partner.  Further studies with mutant Cx46 proteins that are defective 
in phosphorylation sites or kinase binding sites are required to unravel the mechanism of Cx43 
degradation upon Cx46 overexpression. Studies elucidating the roles of various cellular 
compartments aiding in the interaction between Cx43 and Cx46 would also provide insight into 
which kinases or other binding proteins are involved in the reciprocal relationship. 
Our results can be extended to understand the molecular mechanism of connexin-
influenced regulation of oncogenesis. Cx43 has anti-tumor properties and expression of Cx43 
can be down-regulated in tumors (22-25). Moreover, in previous studies, we have shown that 
Cx46 is up-regulated in breast tumor samples, MCF-7 and Y79 retinoblastoma xenografts, and 
acts as an oncogene to favor early tumor growth (24, 25). Therefore, we speculate that up-
regulation of Cx46 promotes tumor growth by inducing the degradation of the tumor suppressor 
protein Cx43. Indeed, in a recent study we have found that the downregulation of Cx46 by 
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siRNA inhibited Y79 retinoblastoma xenograft tumor growth which was associated, 
interestingly, with an increase in Cx43 protein levels in vivo (25). 
In conclusion, our data indicate that Cx43 and Cx46 are expressed and regulated in a 
reciprocal manner in lens epithelial cells. Depletion of Cx43 is associated with an upregulation 
of Cx46 and both processes are mediated by PKC. We also provide evidence that endogenous 
Cx43 regulates endogenous Cx46 at the protein level. Exogenous expression of Cx46, on the 
other hand, induces degradation of Cx43. The C-terminal tail domain of Cx46, which has less 
sequence similarity with other connexins, is required to induce degradation of Cx43. The 
ubiquitination of Cx43 is strongly increased in Cx46 over-expressing cells and proteasome 
inhibitors counteract Cx43 degradation. Therefore, Cx46-induced Cx43 degradation is likely to 
be mediated via the ubiquitin-proteasome pathway in the perinuclear region of lens cells, 
although the exact cellular mechanism warrants further characterization. 
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Chapter 5 - Summary and Conclusions of Work Presented 
In summary, this work has provided insights into why Cx46 is unique to hypoxic 
environments.  I have shown that Cx46 protein up-regulation is associated with hypoxic 
environments and that Cx43 is negatively affected by the CT domain of Cx46.  I have also 
shown that Cx46 ablation is an effective anti-tumor growth therapy with the mechanism of action 
correlating with an up-regulation of anti-tumor Cx43 protein.  Additionally, I have provided 
insight into the hypoxic regulation of Cx46 at the gene level which suggests that Cx46 is tightly 
controlled in a tissue and time-dependent manner. 
This work has led me to uncover an additional biological role of Cx46.  The protein 
seems to be important to mitigate the hypoxic insults encountered in a low oxygen environment.  
While it is nearly impossible to detect and measure the type of molecules that traverse individual 
pores with the current state of channel technology, one can suggest that metabolites, both basic 
and toxic, are passed freely between cells connected with Cx46 gap junctions.  This is inferred 
from the lens where it is avascular and hypoxic in nature.  Cx46 comprises the majority of 
functional gap junction channels in the mature fiber cells and loss of function results in cataract 
by enhanced oxidation and degradation of structural proteins such as crystallins.  Cx46 channel 
function is critical to prevent oxidation-based cataracts.  This may be true in solid tumors as well 
where Cx46 becomes up-regulated in the hypoxic environment of the tumor. 
We propose that the function of Cx46 in hypoxic tissues is related to the hypoxic growth 
state of the tumor, where Cx46 functions as a molecular portal in which necessary metabolites 
and molecular signals are shared more efficiently than metabolite paracellular diffusion and 
uptake.  Prevention of Cx46 mRNA translation by siRNA treatment in solid tumors results in 
slow growing or even halted tumor growth, suggesting that Cx46 channels are needed for 
expansion of the tumor mass.  Once vascularization occurs, Cx46 channels no longer would be 
needed but may persist due to tumor transcription factor expression.  This certainly can be the 
case since many lens crystallins are expressed in solid tumors, as discussed in the introduction of 
this dissertation.  This hypothesis needs to be tested further to confirm. 
 The mechanism of action we propose in the lens and tumor follow similar 
patterns.  Figure 5.1 demonstrates the mechanism in schematic detail.  As Cx46 becomes up-
regulated by the increasing hypoxic environment, Cx43 expression halts and the protein becomes 
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degraded by perinuclear (most likely Golgi) interactions with Cx46 protein in a ubiquitin-
dependent manner.  In the cytoplasm, Cx46 may interact with Cx43 at the plasma membrane, as 
suggested by the CT domain experiments.  The Cx46 tail domain may bring ubiquitin ligases 
specific for Cx43 to the gap junction plaque, therefore enhancing the Cx43 ubiquitination effect 
and subsequent degradation.   
Of note is the natural pattern of connexin expression in the lens where Cx50 is expressed 
in all regions whereas Cx43 is only in the oxygenated epithelia and Cx46 is the hypoxic fiber cell 
region.  We believe Cx43 is affected by the increase in Cx46 by the transitioning transcription 
factor expression present in the differentiating and hypoxic fiber cells.  Cx46 could be 
upregulated in this area of the lens where Cx43 expression could be halted and the remaining 
Cx43 protein being affected by the Cx46 protein.  Cx46 persists into the hypoxic lens where 
Cx43 protein is not found.   
Therefore, we present a mechanism where induction of Cx46 is concurrent with the 
halting of Cx43 production and where Cx46 is responsible for the enhanced destruction of Cx43 
gap junction plaques in lens cells.  Cx46 functions as an important channel molecule for hypoxic 
survival and expression of Cx46 can be turned on in hypoxic environments when it is most 
needed to perform similar to vasculature.
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Figure 5.1 Proposed Regulatory Mechanism of Action between Cx43 and Cx46 in the Lens 
Cx43 is degraded by Cx46 protein interaction at the ER/Golgi and the cellular membrane in gap junction plaques.  Degradation is proposed to occur via the 
endoplasmic reticulum associated degradation (ERAD) scheme and by enhanced Cx43 gap junction destruction by ubiquitin signals. This is proposed to occur in 
solid tumors as well as in the lens where this mechanism can explain the connexin protein patterning that was observed during our studies.
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Abbreviations Used 
Standard biochemical and molecular biology abbreviations assumed. 
A 
AT  Amino-terminal 
B 
bHLH  basic helix-loop-helix protein domain 
C 
CK1   Casein kinase 1 
CT domain  Carboxy-terminal domain of each connexin; sequence after TM4 
CMTX  Charcot-Marie-Tooth disease, X-linked  
CMV  Cytomegalovirus  
CNS  Central nervous system 
Cx   Connexin protein 
D/E 
EGFP   Enhanced green fluorescent protein 
ER   Endoplasmic reticulum 
ERAD  Endoplasmic reticulum-associated degradation 
EL  Extracellular loop 
F 
FITC   Fluorescein isothiocyanate 
G 
GJ  Gap junction 
GJIC Gap junction intracellular communication 
GPCR G-protein coupled receptor 
H 
HIF  Hypoxia-inducible factor 
HLEC  Human lens epithelial cell 
HRE  Hypoxia response element 
Hyp  Hypoxia 
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I 
IRES  Internal ribosome entry site 
IL  Intracellular loop 
J/K/L/M/N 
N2A  Mouse neuro2A cell 
N/N1003A Rabbit lens epithelial cell 
Norm  Normoxia 
NT  Amino-terminal domain 
O 
ODDD  Oculodentodigital dysplasia, malformation 
OFZ  Organelle-free zone 
P 
PAS  Per-Arnt/AhR-Sim-like protein domain 
PET  Positron emission tomography 
PGE2  Prostaglandin E2 
PKCγ  Protein kinase C, gamma isoform  
PM   Plasma membrane 
Q/R 
RACE  Rapid amplification of cDNA ends 
ROS   Reactive oxygen species – superoxide, peroxides, free radicals 
S/T 
TCA  Tricarboxylic acid 
TGN   Trans-golgi network 
TPA  12-O-tetradecanoylphorbol-13-acetate 
TM  Transmembrane 
TSS  Transcription start site 
U 
UTR  Untranslated region 
V/W/X/Y/Z 
WB   Western blot 
